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Stability is an essential quality attribute for pharmaceutical formulations. 
Evaluation of drug stability can prevent toxicity and increase safety, efficacy and quality 
of the final drug product. In this work, various factors affecting stability of both small 
molecule and biopharmaceutical compounds were investigated. In the first study, we 
initially hypothesized that albendazole, a poorly water soluble drug, could be prepared by 
melt extrusion to enhance its dissolution and bioavailability. However, it was found that 
albendazole was severely degraded by heat and shear during extrusion. When combined 
with methanesulfonic acid and Kollidon VA 64, amorphous albendazole solid dispersion 
was successfully prepared by an alternative process, spray drying, to enhance dissolution 
and shelf-stability. In the second study, the stability of a caveolin-1 scaffolding domain 
(CSP7), which is a newly developed peptide for the treatment of idiopathic pulmonary 
fibrosis, was investigated in order to achieve an optimal formulation for in vivo clinical 
studies. This study showed the physical instability of the peptide, which was aggregation 
induced by moisture, and the crystallization of bulking agent on its stabilizing effect. It was 
found that the moisture-induced aggregates were reversible and could be prevented by pH 
adjustment and incorporation of lactose in the composition. Lactose, a reducing sugar, 
stabilized the peptide possibly as a result of chemical interactions with CSP7 (e.g., 
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formation of a Schiff base with the N-terminal amino group of CSP7). Based on these 
results, lactose stabilized CSP7 against moisture-induced aggregation in the solid state to 
a greater degree than mannitol. Additionally, stability of the CSP7-bulking agent 
formulations was not affected by nebulization using vibrating mesh nebulizers. Lastly, the 
effect of nebulization using vibrating mesh nebulizers on stability of tissue-type 
plasminogen activator (tPA) and single-chain urokinase plasminogen activator (scuPA), 
being studied for the treatment of inhalational smoke-induced acute lung injury (ISALI), 
was evaluated. For scuPA, the effect of lyophilization on its stability was also studied. The 
results showed that scuPA was stable after lyophilization (scuPA) and that both proteins 
were stable following reconstitution and nebulization. There were only slightly differences 
between the active and passive vibrating mesh nebulizers. In conclusion, from our work, 
the physical and chemical stability of small- and macromolecules was affected by 
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Chapter 1:  Stability of Pharmaceutical Formulations 
  
1.1 INTRODUCTION 
The term “pharmaceutical formulations” is defined as “the processes whereby a 
drug is transformed into a suitable drug product for administration to a patient by a 
particular route” (1). During formulation development, clinical studies and marketing, 
stability is the critical quantity, playing an essential role as performance attributes, that 
needs to be evaluated (2). The instability of the drug not only impacts the potency, purity 
and safety of the drug formulation, but can also lead to formation of toxic degradants (3). 
Stability assessment of drugs since early phase of product development plays a crucial role 
in providing evidence to explain the root causes or mechanisms of product instability. Thus, 
the purpose of the following discussion is to give an overview considering chemical and 
physical stability of both small- and macromolecules (biologics/biopharmaceuticals, 
peptide/protein are used interchangeably throughout this chapter) during formulation 
development. For small molecule drugs, stability of amorphous solid dispersions of poorly 
water soluble drugs will be primarily discussed. On the other hand, for macromolecules, 




1.2 FACTORS INFLUENCING STABILITY OF PHARMACEUTICAL FORMULATIONS 
A variety of factors influencing the stability of a pharmaceutical product include 
the stability of active ingredient(s), drug-excipient interaction, manufacturing process, 
dosage form, packaging, shipping, storage and handling (4). Drugs exposed to many 
conditions, such as heat, pH and moisture during the development process can also cause 
instability (4). In addition, degradation reactions such as hydrolysis, oxidation, reduction, 
or racemization are also induced by some conditions such as concentration of reactants, 
pH, radiation, catalysts as well as aging of the raw materials themselves (4).  
Similar to the small molecule drugs, stability of the macromolecules is also affected 
by the common factors such as temperature, light, moisture, pH, shear (agitation), oxidation 
and protein concentration (5,6). However, there are some other factors such as buffer 
components and concentration, ionic strength and the presence of excipients that also affect 
the stability of the macromolecules (7–11). 
Therefore, a basic understanding of the most common factors affecting a drug and 
its formulation stability is needed for process design, storage and packaging of the drug 
product (6,12,13). In particular, the understanding of the cause and mechanism of drug 
instability/inactivity provides the rational development of formulations to minimize 
degradation and therefore maximize the storage stability of the drug product (14). 
Examples of the factors affecting the stability of formulations are provided below. 
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1.2.1 Temperature 
The most significant variable affecting drug stability is temperature (15). 
Relationship between temperature and the rate constant of degradation reactions has 
basically been expressed by the Arrhenius equation (15). From this equation, as 
temperature is elevated higher, the chemical reactions are accelerated.  
Small molecules: The use of thermal processing (e.g. melt extrusion) can cause the 
degradation reactions of thermally sensitive drugs. For example, D9-tetrahydrocannabinol 
(THC) is thermally unstable. The drug itself undergoes severe thermal degradation. Its 
chemical stability in thermal-processed polymer films was studied. In combination with 
carriers such as polyethylene oxide, hydroxypropyl cellulose or antioxidant such as 
ascorbic acid can protect the THC thermal stability (16–18). In Chapter 1, the thermal 
degradation of albendazole by hot melt extrusion is discussed. 
Biopharmaceuticals: For peptide/protein, chemical degradation, physical 
denaturation or both can occur at high temperature. Chemical stability of the 
peptide/protein in solid formulations decreases when exposed to elevated temperature (19). 
Most of the chemical reactions such as deamidation (20), peptide bond cleavage (9), and 
oxidation (21) are accelerated by high temperature. Protein inactivation by high 
temperature is often due to the destruction of disulfide bonds in cystine by b-elimination 
(22). Oliyai et al. reported that the deamidation of the Asn-hexapeptide increases when 
temperature in the solid-state increases (20). For physical stability, when temperature 
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increases, aggregation of insulin also increases (23).  It seems that the increase of mobility 
of the system or the reduction of the activation barrier of the reaction substantially attribute 
to the increase of instability at elevated temperatures. The mobility significantly increases 
with increasing temperature, which may associate with the Tg of an amorphous solid (19). 
In the liquid phase, proteins can be destabilized at low temperatures (such as during 
freeze-drying process). However, unlike most high-temperature denaturation, cold 
denaturation is generally reversible and does not cause much practical problems (24). 
Moreover, temperature during administration such as using some types of nebulizers can 
also generate heat resulting in protein degradation. Temperature control devices may be 
required for the thermolabile drugs (25).  
1.2.2 pH 
Small molecules: pH is the second most important factor affecting drug 
decomposition. Most drug substances are practically stable at the neutral pH, which is the 
pH value in the small intestine. On the other hand, drugs can be decomposed at extremely 
acidic (of the stomach) or alkaline pH (15). pH normally impacts degradation rates of drug 
substances because hydronium and/or hydroxide ions catalyze most degradation pathways 
(15). As mentioned, drug may degrade to the toxic degradants. Pralidoxime degrades by 
two pH-sensitive pathways (acidic and alkaline). However, under alkaline pH conditions, 
cyanide, a toxic product is formed (15,26). The other example is the rearrangement of 
structure of penicillins to penicillenic acids, which are suspected to cause the allergenicity, 
under acidic pH conditions (pH 2 or below) (27).  
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Biopharmaceuticals: pH is also one of the most powerful variables affecting 
stability of the protein formulations. Most protein formulations will survive at pH values 
between 4-9 (28). An extreme pH can cause protein degradation (29). The degradation of 
an Asp-hexapeptide depends on pH of the bulk solution prior to lyophilization. It was 
reported that this peptide degraded under acidic pH conditions (pH 3.5-5.0) and under 
neutral and alkaline conditions (pH 6.5-8.0), however, via the different decomposition 
pathways (9).  
1.2.3 Moisture 
Small molecules: Molecular mobility is a significant factor influencing solid state 
reactivity. Water can act as a plasticizer, which increases the mobility of the matrix and 
this is associated with a higher general reactivity of the matrix components. Consequently, 
to control the moisture, limits for moisture levels of the blend components should be set 
up and monitored. The introduction of water into amorphous molecular level solid 
dispersions at room temperature irreversibly disrupted interactions between the drug and 
polymer resulting in amorphous-amorphous phase separation followed by crystallization 
(30). 
Biopharmaceuticals: Moisture content is a major issue impacting the chemical and 
physical stability of peptide/protein in the solid state (19). Several studies reported 
moisture-induced aggregation of lyophilized biopharmaceutics (e.g. insulin, bovine serum 
albumin, DNA, and tetanus toxoid) (23,31–35). Chapter 3 also reports the results of 
moisture-induced aggregation of the peptide studied. 
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1.2.4 Oxygen (Oxidation) 
Small molecules: Oxidation reactions occur when oxygen is presented, and tend to 
be catalyzed by metal ions. Impurities often catalyze the autoxidation relating reactive 
oxygen-species, which may be hard to reproduce (36). Force degradation study of 
oxidation can be examined under an oxygen atmosphere in the presence of peroxides. 
However, a model of using oxygen is more realistic (37). To characterize the behavior of 
materials stressed by both heat and oxygen, thermo-oxidative stability is tested (38). In 
addition, oxidation reactions can be affected by light. A photosensitizer, which absorbed 
light, can react with molecular oxygen to form the more reactive singlet oxygen species. 
Biopharmaceuticals: In general, oxidation occurs because the side chains of amino 
acids expose to air, residual peroxide from excipients or to visible ultraviolet light. 
Methionine, cysteine, tryptophan, and tyrosine are particularly prone to oxidation. 
Oxidation and other degradation processes can also be catalyzed by metal ions such as iron, 
zinc, copper, or tungsten from metals that are used in the manufacturing process (39,40).   
1.2.5 Shear stress 
Small molecules: A screw extruder, particularly counter-rotating extruder, provides 
high shear stress and intense mixing (41). The energy from the heaters and shearing 
promotes melting. On the other hand, this high energy can lead to degradation of the drug 
as well. Effect of shear stress on drug instability was discussed in Chapter 2. 
Biopharmaceuticals: Regarding biologics, vortexing and shaking can cause shear 
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stresses, which lead to partition proteins to the air-water interface. This promotes physical 
changes such as partial unfolding when exposed to the more hydrophobic air phase (42). 
Interestingly, the human growth hormone remained intact in the absence of any air-liquid 
interface; although, using the homogenizer at the highest shear rate. While in the presence 
of air-liquid interface, the extent of the aggregates increased with higher shear rates during 
homogenization. This is largely attributable to the surface area of the finer dispersion of 
the air in the liquid phase being expanded, due to higher shear (43). 
1.2.6 Excipients 
Excipients can also affect drug stability by various mechanisms (15). Since the 
excipients can act as reactants in chemical reactions, the stability of the drug in formulation 
may be lower than the bulk material (44). Other components in the formulation and/or 
variables can induce chemical reactions between drug and excipient. Therefore, drug-
excipient incompatibility must be studied at the early stage of drug development. 
Small molecules: Several other excipients in melt-extruded formulations are needed 
for specific purposes. A high temperature and shear stress imposed on materials are 
unavoidable in a thermal and mechanical process, particularly hot melt extrusion. For the 
purpose of studying the stability of the formulation, therefore, close monitoring is required 
as not only drug substance but also other excipients would undergo chemical reactions. 
The polymeric carrier, a major excipient in melt-extruded formulations, melts 
during extrusion, encompassing all other components to form the matrix. To achieve the 
successful development of formulation and manufacturing processes, selection of the 
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polymer is critical. The mechanisms of chemical degradation of polymers were reviewed 
(45). Solubility parameters and miscibility of drug-polymer mixtures play an important 
role in prediction of the physical stability of the products. Drug-polymer miscibility will 
be discussed in the following chapter. 
Other excipients such as plasticizer, melt solubilizer, release modifiers, glidants, or 
pigments may also be added to assist processing or modify formulations (46,47). To 
achieve the desired process temperature and to minimize the thermal degradation during 
hot-melt extrusion formulation, plasticizers are added. In some scenarios, however, glass 
transition temperature (Tg) of the formulation was found to be reduced by some 
plasticizers, thus affecting the physical stability of the product. (48,49).  
Selection of excipient is very crucial. As presented above, adding an antioxidant, 
such as ascorbic acid, into the THC formulation helps stabilize the themolabile drug. In 
contrast, the authors also reported that the other antioxidant, vitamin E succinate gave the 
opposite results. The degradation remarkably increased and the stability of the THC 
formulation was reduced (18).  
Biopharmaceuticals: Excipients in peptide/protein formulations are often used to 
stabilize the drugs during processing and/or storage or to serve as a matrix for controlled 
release (40). Several reports presented that crystallization of stabilizing agents such as 
mannitol and glycine, influences the stability of the drugs (11,50–52). The other main 
concern is buffer used since certain buffer salts potentially precipitate during lyophilization 
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and lead to large pH changes (53). The effects of excipients on aggregation of peptide are 
also investigated in Chapter 3.  
1.2.7 Processing methods 
Amorphous solids can be prepared by different pharmaceutical processes, such as 
melt extrusion, spray- and freeze-drying (54). Melting of the drug-polymer mixtures is 
attributed to the heat and shear force of the hot melt extrusion (41). Thus, either high 
temperature or shear stress or their combination can generally cause drug degradation. In 
addition, other variables such as residence time can have an influence on physical and 
chemical stability of the product as well. This will be discussed in Chapter 2.  
Besides the melt processing, spray drying is also widely used to produce solid 
dispersions. Typical inlet and outlet temperatures of the spray dryer are 60-160°C and 40-
90°C, respectively. As discussed in Chapter 2, even though the inlet temperature of the 
spray dryer is high, the drying of the particles is typically very quick (a second up to a few 
seconds) (55). Thus, the high speed vaporization and low outlet temperature of the drying 
chamber can avoid crystallization, and instability of the drug during processing.  
Lyophilization or freeze-drying is another well-known manufacturing approach 
used to prepare both small molecule and biological formulations. In particular, for heat-
sensitive compounds like biologics, lyophilization is often selected. Even if a number of 
peptides/proteins survive the freeze-drying process, some proteins suffer irreversible 
damage during processing (56). Because lyophilization is a multistage process that 
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generates dry materials by removing the solvent(s) and each step is critical (57,58), the 
optimal cycle conditions will lead to a stable formulation.  
1.3 STABILITY OF SMALL MOLECULE DRUGS 
Drug stability and degradation reactions are reviewed in several books (3,15,59). 
Drug that loses potency and contains degradants over the acceptance criteria may be 
considered as unacceptable product. The significant changes of product appearance such 
as color or odor may indicate the instability of the product. The chemical and physical 
stability should be continuously studied to determine the suitable formulation components, 
optimized processing conditions, storage condition, and long-term-stability of the drug 
products.  
1.3.1 Chemical stability of small molecules 
Potency of the drug decreases when it degrades through the chemical reactions. 
Since the drug may degrade to a toxic substance, it is valuable to identify the relevant 
degradants. Several chemical reactions causing degradation include hydrolysis, 
dehydration, isomerization and racemization, elimination, oxidation, photodegradation, as 
well as complex interactions with excipients and other drugs. Drugs are susceptible to 
various degradation mechanisms due to the diversity of molecular structures. Prediction of 
the chemical instability of a drug based on its molecular structure would be beneficial (15).  
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1.3.2 Physical stability of small molecule drugs 
Physical stability such as drug crystallization should be a major concern since it 
generally decreases the dissolution of the amorphous system (30). There are several factors 
affecting physical stability of drug formulation in solid state, particularly amorphous 
pharmaceuticals, such as crystallization, and structure collapse. Amorphous solids are 
physically unstable, which can transform to the crystalline state. Since the advantages of 
amorphous solids are negated by crystallization, the stability of amorphous drugs against 
crystallization is critical for pharmaceutical development (60). However, crystallization 
from the amorphous state can be localized by including some excipients in the formulations 
to stabilize the amorphous state (54).  
Marsac et al. (2010) reported that the miscibility of formulation components 
impacted the physical stability of amorphous solid dispersion (30). Therefore, studying the 
solubility parameters and miscibility of the drug and components prior to formulating the 
amorphous solid dispersions would be very useful to anticipate the physical stability of the 
products. Also, the glass transition temperature (Tg) of the amorphous material is one of 
the most important properties associated with its physical stability.  
Tg is defined as “a temperature at which an amorphous material undergoes a 
transition from a glassy state to a rubbery state” (61). The major cause of physical 
instability of the amorphous systems is the high molecular mobility (62). Therefore, the Tg 
of amorphous materials is correlated with their molecular mobility and physical stability. 
When the temperature is below the Tg of the drug-polymer system, mobility of the 
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molecules is limited and the system remains in the glassy state. Relationship between the 
molecular mobility of small molecules and polymers and their Tg(s) was reported. 
Considerable molecular mobility of amorphous solids exists at the temperatures up to 50°C 
below their Tg(s) (60). As a Tg-50 rule, the amorphous systems are more physically stable 
when the Tg of the system is 50°C above the storage temperature (54). 
1.4 STABILITY OF THERAPEUTIC PEPTIDES AND PROTEINS 
The therapeutic activity of proteins highly depends on their conformational 
structure (57). Owing to their complex structure, the development of stable peptide/protein 
formulations generally require even more resources and effort than the conventional small 
molecule drugs (28). Stability requirements for biologics are also more restrictive than for 
small molecules (63). Therefore, one of the difficulties in commercial development of 
therapeutic peptides/proteins is achieving stability (22). Peptide/protein stabilities can be 
divided into two general groups: chemical stability and physical stability (64). Following 
such physical instability such as denaturation or unfolding, chemical instability of 
peptide/protein in the solid state can also occur (40). Hence, an understanding of the 
chemical and physical stability of biopharmaceuticals can avoid stability problems and 
develop the suitable analytical methods for characterization of drugs and their related 
compounds. It would be more beneficial if the interrelationship between chemical and 
physical instability is known. However, as a result of the smaller size and lesser ordered 
structure, peptides may behave differently from proteins (65). Moreover, each protein may 
also perform differently as well due to their large and complex three-dimensional 
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structures. 
1.4.1 Chemical Stability of macromolecules 
Chemical instabilities of proteins involve covalent modification (make or break 
bonds, rearrangement, or substitution) to generate new molecules (40). There are several 
chemical processes that contribute instability of biopharmaceutics such as deamidation 
(66), oxidation (67), hydrolysis (68), aspartate (Asp) isomerization (69), racemization (70), 
Maillard reaction (71), b-elimination (23), and glycation of proteins (72). The 
susceptibility of peptide/protein to chemical degradation in solution challenges scientists 
in the development of the stable formulations (22). As a consequence, lyophilization has 
been used to prolong shelf life of the protein formulation (73,74). Although lyophilized 
formulation is generally more stable than the corresponding aqueous formulation, chemical 
degradation reactions can still occur (73,74) as reported in some cases that protein stability 
in the solid state is less than or similar to that in solution (75,76). Since peptide/protein are 
frequently prepared in solid-state formulations to prolong the shelf life, this section focuses 
on the chemical degradation of the proteins and peptides in the solid state. The factors 
affecting to chemical stability of proteins/peptide in solid-state are, for example, 
temperature, residual moisture and the excipient(s) included in a formulation (40) as 
described above.  
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1.4.2 Physical Stability of macromolecules 
Owing to the polymeric nature of the proteins and their ability to adopt some forms 
of superstructure (secondary, tertiary, and quaternary), proteins can undergo various types 
of structural changes (22). The physical stability of a protein relates to maintaining the 
native secondary and higher order structure. The meaning of physical instability of protein 
is any process by which the physical state (three-dimensional conformational integrity) of 
the protein changes without any change in the chemical composition (64). However, 
physical instabilities may result from chemical instabilities such as deamidation and 
disulfide bond cleavage and vice versa (40). Typically physical instability of proteins 
includes four processes: denaturation, aggregation, precipitation and surface adsorption 
(22). “Precipitation” is the term used to denote insolubility rather than insoluble aggregate 
formation.  
1.5 STABILITY OF THE NEBULIZED BIOPHARMACEUTICALS 
Direct drug delivery to the site of action provides high drug concentrations, 
minimizes systemic exposure and increases therapeutic effects and safety (77–79). 
Comparing with other devices for pulmonary delivery, nebulization of biologics directly 
to the lung is easier, faster and most used to formulate and test a new drug model (80). 
However, there was a report on stability issue with biopharmaceutics when using nebulizer 
(81). In some atomization process, shear stress and heat may damage the drugs (80). Since 
the biopharmaceuticals are more susceptible to the physical stress (shear stress and heat) 
produced by the atomizers than small molecule, their pharmacological activity could be 
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affected during nebulization (29,80). In addition, the solution formulations are more 
susceptible to the effect of the factors than suspension formulations (29). Thus, the 
challenge of inhalation technologies for biopharmaceutical compounds is to maintain their 
therapeutic activity until the drugs access to the lung. The evaluation of nebulization 
process is significant for the development of peptide/protein formulations. 
The nebulizers are categorized according to the mechanism of atomization into 
three types; jet, ultrasonic, and vibrating-mesh nebulizers (29,80). Relevant factors 
affecting biopharmaceutics degradation and inactivation depend on the basic mechanism 
of aerosol generation (29). Air-jet and ultrasonic nebulizers by design suffer from 
recirculation. In brief, the droplets are repeatedly nebulized for at least 10-15 times 
resulting in an increase in interfacial stress (82,83). Ultrasonic nebulizers can also generate 
heat, which can cause negative effects on heat-labile compounds such as proteins or 
peptides (84). On the other hand, the vibrating mesh nebulizers are single-pass devices by 
design that can prevent the repetition of nebulization stress (85) and do not generate heat 
during operation (86). Thus, vibrating mesh nebulizers are currently the most suitable 
devices for pulmonary protein/peptide delivery. In conclusion, owing to factors of 
biologics degradation and inactivation, the vibrating mesh nebulizers have been 
recommended to aerosolize peptide/protein formulations (87,88) since they gently generate 
the aerosol plume (89,90) with low shear stress (91). In Chapter 3 and Chapter 4, the 




Stability is a critical issue that must be assessed during the drug development 
process. Drug instability can occur not only in the liquid state, but also in the solid state. 
The common factors that must be studied include temperature, pH, moisture, oxygen, shear 
stress and excipients. Processing technique and device type for drug delivery can also cause 
drug degradation. The small- and macromolecules have both similar and different relevant 
factors affecting the stability of their formulations. Macromolecules tend to be less stable 
than the small molecules due to their complex structures and various functional groups.   
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Chapter 2: Hot Melt Extrusion versus Spray Drying: Hot Melt 




The purpose of this study was to enhance the dissolution properties of albendazole 
(ABZ) by the use of amorphous solid dispersions. Phase diagrams of ABZ-polymer binary 
mixtures generated from Flory-Huggins theory were used to assess miscibility and 
processability. Forced degradation studies showed that ABZ degraded upon exposure to 
hydrogen peroxide and 1 N NaOH at 80°C for 5 min, and the degradants were albendazole 
sulfoxide (ABZSX), and ABZ impurity A, respectively. ABZ was chemically stable 
following exposure to 1 N HCl at 80°C for one hour. Thermal degradation profiles show 
that ABZ, with and without Kollidon® VA 64, degraded at 180°C and 140°C, respectively, 
which indicated that ABZ could likely be processed by thermal processing. Following hot 
melt extrusion ABZ degraded up to 97.4%, while the amorphous ABZ solid dispersion was 
successfully prepared by spray drying. Spray-dried ABZ formulations using various types 
of acids (methanesulfonic acid, sulfuric acid and hydrochloric acid), and polymers 
(Kollidon® VA 64, Soluplus® and Eudragit® E PO) were studied. The spray-dried ABZ 
with methanesulfonic acid and Kollidon® VA 64 substantially improved non-sink 
dissolution in acidic media as compared to bulk ABZ (8-fold), physical mixture of 




observed in the spray-dried product for up to 6 months and less than 5% after 1-year 
storage. In conclusion, amorphous ABZ solid dispersions in combination with an acid and 
polymer can be prepared by spray drying to enhance dissolution and shelf-stability, 
whereas those made by melt extrusion are degraded. 
2.1 INTRODUCTION 
Successful treatment of infections of the liver, lung, and peritoneum caused by 
worms with drugs in the benzimidazole group, including albendazole (ABZ), depends on 
the plasma concentration of the drug [1] . However, ABZ is practically insoluble in water 
as a BCS class II drug [2]. Its low water solubility leads to an extremely low (< 5%) 
systemic absorption [3]. Dissolution is an important limiting step of ABZ absorption, so 
enhancement of the dissolution is expected to result in greater bioavailability [4]. Various 
strategies have been developed to improve oral bioavailability of ABZ, such as 
administering the drug with a fatty meal [5] or using surfactants [6], nanosuspensions [7], 
co-grinding with water soluble polymers [8], nanocrystals [9], salt formation [10] and solid 
dispersions [11,12]. However, to our knowledge, combinations of salt and amorphous solid 
dispersions of ABZ have not been reported. 
Amorphous solid dispersions are desirable to improve drug solubility since 
amorphous drugs exist in a high energy form which contributes to the increased solubility, 
however, they are not thermodynamically stable and are prone to recrystallization. The 




rational approaches for guiding the selection of drug-polymer compositions and processing 
parameters to obtain stable amorphous solid dispersions [13–16].  
Ideally, a water-insoluble drug and hydrophilic carrier(s) are homogeneously mixed 
at the molecular level to form an amorphous solid dispersion. Hot melt extrusion (HME) 
and spray drying are well-known processing techniques for preparing solid dispersions 
[17,18]. HME is a solvent-free continuous thermal process, which transforms discrete 
particles of drug and polymeric carrier(s) into a glassy state product. The quality of the 
extruded product depends on the processing parameters (e.g., screw configuration, 
processing temperature, screw speed, and feed rate) and properties of the components (e.g., 
glass transition temperature (Tg), solubility and stability) [18,19]. For higher melting point 
drugs (normally those with high molecular weight), the drug particles may not be melted 
during processing, but dissolved into the rubbery polymer. The high molecular weight 
drugs containing various types of atoms and functional groups can lead to higher propensity 
to degradation including thermal degradation. The balance between mixing efficiency and 
thermal exposure to achieve the desirable safety and efficacy of the products must be 
evaluated  [19]. On the other hand, spray drying is a solvent-based method that transforms 
a solution (or suspension) of drug and excipient(s) into a glassy state. Process parameters 
of spray drying (e.g., inlet and outlet temperatures, feed flow rate and types of atomization 
nozzles) and properties of compositions of the formulation (e.g., carrier, solvent, and solid 
content) also substantially affect product quality [20]. HME has many advantages over the 




drugs [21]. The drug candidates processed by HME have to be exposed to elevated 
temperatures and shear stress in the equipment for a long period of time, so they may 
decompose during the process [21,22]. A recent study mentioned about the shear stress and 
energy input affecting the recovery of carbamazepine during the extrusion [23]. 
The present study compares dissolution performance and purity of solid dispersions 
of ABZ made by HME and spray drying. The objective of this study is to enhance the 
dissolution performance of ABZ by preparing solid dispersions made by spray drying and 
hot melt extrusion. To our knowledge, there are no reports of thermal degradation, 
solubility parameters, or phase diagrams of binary mixtures of ABZ and carriers. 
Therefore, the applicability of modeling ABZ and polymer miscibility based on Flory-
Huggins theory is studied. 
2.2 MATERIALS AND METHODS 
2.2.1 Materials 
Albendazole (ABZ) was purchased from Molekular (Irvine, CA). Kollidon® VA 
64 and Soluplus® were kindly donated from BASF (Florham Park, NJ). Eudragit® E PO 
was generously donated from Degussa GmbH (Linden, NJ). Tetrahydrofuran (THF) with 
butylated hydroxytoluene (BHT) was purchased from Thermo Fisher Scientific (Hudson, 
NH). All other chemicals and solvents used were American Chemical Society (ACS) 




2.2.2 Preformulation studies 
2.2.2.1 pH solubility profile and pKa  
Buffer species were prepared as per USP 36 [24], ranging in pH values from 1.2 to 
9. For pH 1.2, USP-simulated gastric fluid (without pepsin) was used. An excess of 
crystalline ABZ was added to each glass vial containing buffer media. The vials were 
placed in the shaker (Environ Orbital Shaker, Lab-Line Instruments, Melrose Park, IL, 
USA) at 100 rpm shaking speed, at 37°C, in the absence of light. The aliquot samples were 
collected after 12, and 24 hours, centrifuged and filtered through 0.22 μm, 13-mm 
polyvinylidene difluoride (PVDF) syringe filters. Samples were properly diluted with 
methanol, and the concentration of ABZ was measured using HPLC as described below. 
The pKa of ABZ in buffer at 37°C was calculated from the pH solubility profile and the 
modified Henderson-Hasselbalch equation [25].  
!"#$ = !"# $& + 	 !"#(1 + 10,-./,0) 
 where S0 is the intrinsic solubility, S is the solubility at a given pH, and pKa is a pH at 
which the concentration of unionized and ionized forms of a monoprotic drug in the 
solution are equal. 
2.2.2.2 Forced degradation study 
ABZ was exposed to stressed conditions including acid, basic, oxidation, and 
thermal degradation [26]. Firstly, a stock solution of 1 mg/mL ABZ was prepared by 




methanol. For acid stressed degradation, 1 mL of the stock solution was exposed to 1 mL 
of 1 N HCl for 2 hours and 1 hour at 25°C and 80°C, respectively. The reaction was then 
stopped with 1 mL of 1 N NaOH and diluted to volume (10 mL) with methanol. On the 
other hand, the alkaline stressed condition was achieved by adding 1 mL of 1 N NaOH to 
the ABZ stock solution. The exposure times were 1 hour, and 5 min, at 25°C and 80°C, 
respectively. The reaction was quenched by 1 mL of 1 N HCl and the sample was diluted 
with methanol. Oxidative degradation was carried out by reacting 1 mL of ABZ stock 
solution with 1 mL of 3% hydrogen peroxide (H2O2) solution at 25°C and 80°C for 1 hour 
and 5 min, respectively, and diluted with methanol. For the thermal degradation, the sample 
solution was heated to 80°C for 2 hours and diluted with methanol before being tested. All 
samples were analyzed using HPLC and LC/MS. 
2.2.2.3 Thermal stability profile 
Thermal analysis was performed using a Q20 modulated differential scanning 
calorimeter (mDSC) (TA Instruments, New Castle, DE, USA) to determine the thermal 
degradation profile of ABZ with or without a polymer. The instrument was calibrated using 
the standard, indium, prior to use. Bulk ABZ and its physical mixture with Kollidon® VA 
64 (20:80) of 6.0 ± 0.1 mg were weighed into the aluminum DSC pans and heated and 
equilibrated at each temperature for 5 min with 50 mL/min of nitrogen flow. Samples were 
studied at 10°C intervals over a range of 80°C to 220°C. After 5 min, the sample was 




volume with methanol. Sample solutions were analyzed by HPLC to investigate the 
influence of polymers on the degradation temperature of ABZ.  
2.2.3 Drug-polymer miscibility model 
2.2.3.1 Melting point depression approach 
Prior to running the experiments, drugs and polymers were dried in a vacuum oven 
for 24 hours. The test method was adapted from a previous study [19]. In short, physical 
mixtures of ABZ and each polymer were prepared at concentrations of 0%, 5%, 10%, 15%, 
20%, and 25% polymer by volume for ABZ systems. Each composition was weighed into 
an aluminum pan at 6.0 ± 0.1 mg. Triplicate samples were prepared at each concentration. 
The onset of melting endotherm and the melting temperature of the ABZ, in the presence 
of a polymer, were measured with an mDSC equipped with a refrigerated cooling accessory 
(DSC 2920, TA Instruments, New Castle, DE, USA). A ramp rate of 1°C/min, from 30°C 
to 250°C modulating every 60 sec at an amplitude of 1°C with 50 mL/min of nitrogen gas, 
were exploited as a running condition for all samples. Glass transition temperatures (Tg) 
were also determined for the drug concentration–Tg profile. The heat–cool–heat cycle was 
used to heat the sample to 210°C, quench-cool to remove thermal history, and re-heat to 
measure the Tg of samples at different drug–polymer ratios. 
2.2.3.2 Hansen solubility parameter (δ) 




group contributions using Molecular Modeling Pro software (Chem SW Inc., Fairfield, 
CA). The summary of the three fractions is shown in Equation 1 [27].  
δ2 = δd2+δp2 + δh2          Equation 1 
where δ is the total solubility parameter, δd is dispersion forces, δp is polar interactions of 
the functional groups in the molecule, and δh is hydrogen bonding energy. Miscibility of 
the binary mixture system was evaluated from the difference in solubility parameters 
between ABZ and polymer (Dδ).   
2.2.3.3 Flory–Huggins Theory 
Flory–Huggins theory was applied to generate the Gibbs free energy of mixing and 
a phase diagram of the ABZ–polymer binary system. The relative contribution of entropy 
and enthalpy to the mixing free energy of ABZ-polymer systems is as described in 
Equation 2.  
 2345 = 	∆7345 − 	T∆$345     Equation 2 
where 2345 is the free energy of mixing, ∆7345	is the enthalpy of mixing, T is the absolute 
temperature, and ∆$345 is the entropy of mixing.  
In addition, Equation 3, Gibbs free energy of mixing was evaluated in terms of the 
volume fractions of the drug, :, and the Flory–Huggins interaction parameter, ;.   
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where 2345 is the free energy of mixing, R is the universal gas constant, T is the absolute 
temperature, CDEFG and C,HIJ3KE are the number of moles of the drug and the polymer, 
respectively, :DEFG is the volume fraction of the drug and :,HIJ3KE is the volume fraction 
of the polymer [28–30]. Molar volume per Flory–Huggins lattice size, was also calculated 
using Molecular Modeling Pro software and the χ is considered as a function of 
temperature as described in the literature [16,31]. The values of χ at various temperatures 
were calculated by a linear equation of two points of data (χ) at ambient temperature (about 
25 °C). Gibbs free energy of different temperatures was diagrammed.  
The second derivative of Equation 3 was set to 0 and f was defined as a function 
of c. This equation determines the spinodal curve, which is the borderline between 
metastable and unstable zones. Equations 4 and 5 result in the binodal curve, which is the 
phase boundary between metastable and stable zones. The curve is plotted by building the 
common tangents of the free energy at the compositions and corresponding to the 
equilibrium of two phases [19,32].  












	     Equation 4 
and  
















The spinodal and binodal curves intersect at the critical point, which was calculated from 
the third derivative of Equation 2.  
2.2.3.4 Glass transition temperature (Tg) of the solid dispersion 
The Tg of the solid dispersion is given by the Gordon-Taylor equation [33]. 
   V# = 	WXYZX[-W\YZ\	
WX[-W\
                              Equation 6 
where Tg, Tg1, and Tg2 are the glass transition temperatures of the solid states and the two 
different components, respectively: ] is the weight fraction, and the ^ is a constant 
approximately calculated from Equation 7. 
   ^ ≈	
`X	OZX
`X	OZ\
              Equation 7 
2.2.3.5 Experimental model 
Solid dispersions of ABZ-Kollidon® VA 64 and ABZ-Soluplus® at 10%, 20% and 
30% drug loadings and 1%, 5%, 10% and 20% drug in Eudragit® E PO matrices were 
produced. The HAAKE Mini-Lab Micro Compounder (Thermo Electron, Germany) was 
run at 140°C for the Kollidon® VA64 and Soluplus® formulations, and at 120°C for 
Eudragit® E PO with a screw speed of 150 rpm. Forming of the single-phase, metastable 
or two-phase unstable mixture was confirmed using visual observation and a powder X-
ray diffractometer (Phillips Electronic Instrument, NY) at the 2θ range of 10-40°, step 




2.2.4 Formulation of solid dispersions  
2.2.4.1 Hot melt extrusion  
ABZ and Kollidon® VA 64 were dried in an oven (ON-12G, Jero Tech, Kyunggi-
do, Korea) for 24 hours prior to extrusion. The homogeneous blend of 20% w/w ABZ was 
fed at a feed rate of 1.5 g/min to a Nano-16 twin-screw extruder (American Leistritz 
Extruder Corp. USA, Somerville, NJ) equipped with a 5-mm diameter die. The screw 
design used is shown in Figure 2.1.  
During the extrusion process, ethanol (absolute, 99.5% v/v dehydrated with 
molecular sieve) was injected into the injection zone, and a vent to atmosphere was located 
in the venting zone (Figure 2.1) using an HPLC pump. The barrel temperature, screw 
speed, and flow rate of solvent were varied as listed in Table 2.1. Upon ejection, the 
extrudate was air-cooled on a conveyor to room temperature, dried in an oven overnight, 
and subsequently milled. Particles smaller than 250 µm were stored in airtight glass 




































Die 4 3 2 1  
1 120 120 120 110   X 100 1.5 - - 14.2 300 
2 120 120 120 110 X 200 1.5 - - 13.2 200 
3 120 120 120 110 X 300 1.5 - - 11.3 200 
4 120 120 120 110 X 150 1.5 Ethanol 0.2 7.4 50 
5 120 120 120 110 X 150 1.5 Ethanol 0.5 6.4 65 
6 120 120 120 110 X 300 1.5 Ethanol 0.5 5.4 45 
7 110 110 110 100 X 300 1.5 Ethanol 0.5 5.9 40 
8 100 100 100 100 X 300 1.5 Ethanol 0.5 6.6 30 
 




2.2.4.2 Spray drying 
ABZ and polymer(s) (20:80 w/w) were dissolved in THF containing hydrochloric 
acid, sulfuric acid or methanesulfonic acid. The weight ratio of ABZ:acid was 1:1, and the 
total solid content of each solution was 5% w/v. Solutions were fed into a Buchi Mini Spray 
Dryer 290 (Buchi, Flawil, Switzerland) with a co-axial nozzle with co-current flow. The 
inlet temperature at the drying chamber was maintained at 100 ± 5°C and the outlet 
temperature was 60 ± 5°C. The aspirator and pump were set at 100 m3/h and 20%, 
respectively. The resulting particles were collected by a cyclone and then vacuum dried at 
30°C for 24 h. The fine powder was stored in airtight glass containers in a desiccator. 
Physical mixtures (PM) of ABZ and polymer(s) in the same weight ratio were used as 
controls.   
2.2.5 Characterization of solid dispersions 
2.2.5.1 Powder X-Ray Diffractometry (PXRD) 
Morphology of the powder samples was investigated using a Benchtop X-ray 
diffraction instrument; Model Miniflex 600 (Rigaku, Woodlands, TX) with primary 
monochromated radiation (CuK radiation source, l = 1.54056 Å). The instrument was 
operated at an accelerating voltage of 40 kV and 15 mA. All samples were subjected to the 
same program; scanned over a 2q range of 5° to 40° at a step size of 0.04°/sec, a dwell time 




2.2.5.2 Differential Scanning Calorimetry (DSC) 
The thermal properties of formulations were conducted using a modulated 
differential scanning calorimetry. Each sample of approximately 3 mg was loaded into a 
standard aluminum pan. Experiments were performed at a heating ramp rate of 10°C/min 
in the range of 30-250°C, with a modulation temperature amplitude of 1°C/min and 
nitrogen purge of 50 mL/min.  
2.2.5.3 Thermogravimetric Analysis (TGA)  
Thermal stability of ABZ, each polymer and the resulting formulations were 
determined using a thermogravimetric Analyzer (TGA/DSC 1, Mettler Toledo, Columbus, 
OH). Approximately 3 mg of each sample was weighed into a separate crucible and 
covered with a lid. The crucible was placed in the chamber with a constant flow of nitrogen 
(50 mL/min), and equilibrated at 30°C. Once equilibrated, the sample mass was monitored 
and plotted as a function of temperature from 30°C to 250°C at a scan rate of 10°C/min. 
2.2.5.4 Scanning electron microscope (SEM) 
The morphology of spray-dried particles was evaluated using a scanning electron 
microscope (SEM). Prior to imaging, samples were coated with platinum/palladium, 
targeted for 12 nm thickness, under high vacuum using a Cressington 208 Benchtop Sputter 




(Carl Zeiss, Oberkochen, Germany) operated under vacuum, at an accelerating voltage of 
5 kV of Electron High Tension (EHT).  
2.2.5.5 Particle size distribution of spray-dried particles 
The particle size distribution of ABZ and the spray-dried formulations was 
determined using a particle size analyzer with laser diffraction, Helos and Rodos T4.1 
dispenser (Sympatec, Clausthal-Zellerfeld, Germany). The powders were dispersed at the 
primary pressure of 3 bar and a rotation speed of 50%.  
2.2.6 ABZ salt preparation 
Three ABZ salts (mesylate, sulfate and hydrochloride) were produced in order to 
compare the non-sink dissolution with the spray-dried ABZ (non-salt form) solid 
dispersions. The preparation methods were adapted from [10]. Five grams of bulk ABZ 
was dispersed in 500 mL THF. Each acid (methanesulfonic acid, sulfuric acid or 
hydrochloric acid) in a 1:1 molar ratio (ABZ:acid) was added into the slurry and stirred at 
room temperature until the solution was clear. Dried materials were obtained when THF 
completely evaporated in a fume hood at ambient temperature. In particular, the off-white 
ABZ hydrochloride was received after re-dissolving the material yielded from the first step 
by 500 mL of ethanol. The ethanol was again evaporated at ambient temperature to obtain 
the final hydrochloride salt. The milled powders (250 µm) were characterized by 1H NMR, 




2.2.7 Non-sink dissolution  
Non-sink dissolution analysis was performed using an SR8 Plus dissolution tester 
(Hanson Research Corp., Chatsworth, CA) equipped with mini paddles. Spray-dried 
formulations equivalent of 700 mg ABZ were added into dissolution vessels containing 
100 mL of simulated gastric fluid without pepsin (10X equilibrium solubility). The vessels 
were maintained at 37 ± 0.5°C with rotating speed of 50 rpm. Test samples were studied 
in triplicate, with 3-ml samples withdrawn from the vessels at 5, 10, 15, 30, 45, 60, 90 and 
120 min. The drawn volume was replaced with the warmed blank medium. All samples 
were immediately filtered through 0.22 µm PVDF syringe filters, and diluted with the 
dissolution medium. Samples were then analyzed as described in Section 2.2.8.  
2.2.8 Chromatographic analysis 
ABZ samples were tested using a Dionex 3000 (Thermo Fisher Scientific, Fair 
Lawn, NJ) HPLC system. The analytical method was modified from the USP 36 
monograph for albendazole tablets [34]. The HPLC system was equipped with a UV-Vis 
detector and run at ambient conditions. ABZ was eluted by an Inertsil® ODS-2 
(4.6 × 150 mm) column (GL Sciences, Tokyo, Japan). The mobile phase was 4.35 mM 
monobasic ammonium phosphate and methanol (40:60 %v/v) and the flow rate was 1.5 
ml/min. A 20 µL aliquot was injected onto the column and chromatograms were acquired 





2.2.9 Long term stability study of spray-dried formulation 
Long-term stability studies of the spray-dried formulation were conducted by 
storing samples in a desiccator at 25°C.   
2.3 RESULTS AND DISCUSSION 
2.3.1 pH solubility profile and pKa value 
Figure 2.2A shows the pH solubility profile of bulk ABZ at 37°C. The solubility of 
ABZ was higher at pH values less than 2. ABZ is a weakly basic compound [10] that 
exhibits two pKa’s of 2.8 and 10.26 [3] so the drug is in neutral species between the two 
pKa. It was also observed that ABZ was relatively chemically stable under acidic 
conditions at 37°C for at least 24 hours. ABZ appeared to be more soluble and stable at 
lower pH values. The pKa of ABZ at 37°C was 3.2 (Figure 2.2B), which compared 
favorably to reported values (pKa 3.6) and the calculated pKa of 2.8 from the Hammett 





















Figure 2.2:  pH solubility profile of bulk ABZ at 37 °C (A), and pH solubility profile of 
bulk ABZ at 37°C (concentration are in log S values, the dashed lines were 
linear interpolation of the experimental data) (B) 
2.3.2 Forced degradation study 
The results showed that ABZ was degraded primarily upon exposure to H2O2 and 
1 N NaOH at 80 °C for 5 min. As expected, albendazole sulfoxide (ABZSX) or 
ricobendazole, which is a major active metabolite of ABZ, was the degradation product 
































Figure 2.  pH solubility profile of bulk ABZ at 37 °C (A), and pH solubility profile of bulk  
  ABZ at 37°C (concentration are in log S values, the dashed lines were linear  


































from the oxidative stress condition [35]. ABZ impurity A is a product from alkaline 
catalyzed hydrolysis of the bond in the ABZ molecule. An important by-product from this 
degradation mechanism is methanol. The chemical degradation pathways of these two 
stressed conditions are proposed in Figure 2.3.  
(A) 
            
           
(B) 
       
Figure 2.3:    Proposed degradation pathway of ABZ – oxidation (A), basic hydrolysis (B) 
 
Degradation was not observed following incubation in 1 N HCl at both room 
temperature and 80°C for 2 hours and 1 hour, respectively. ABZ exhibited greater acid 
resistance probably due to the overlapping electron clouds within the amide functional 
groups in the molecule and the corresponding multiple resonance forms [36]. As 











at 80°C and ABZ was chemically stable following exposure at this elevated temperature 
for 2 hours. Nonetheless, the temperatures used with HME and spray drying were higher 
than 80°C, therefore the thermal stability profiles of ABZ at various elevated temperatures 
was studied. 
2.3.3 Thermal stability profile 
Figure 2.4 shows the extent of the remaining drug, as a function of temperature. 
Bulk ABZ and ABZ in combination with Kollidon® VA 64 degraded after storage for only 
5 min at 180°C and 140°C, respectively. The lower degradation temperature of ABZ in the 
polymer mixture may result from the effect of polymer-induced melting point depression 
[38]. Kollidon® VA 64 began softening at its glass transition temperature (101°C) and 
induced drug solubilization at a lower temperature than its melting point (210°C). The 
increase of molecular mobility after the drug melts leads to the enhancement of drug 







Figure 2.4:  Percentage of drug remaining following 5 minutes storage at various 
temperature – crystalline drug substance (A), and physical mixture of drug 
and polymer at 20:80 ratio (B) 
          (A) 
       
        (B)
 
Figure 4.  Percentage of drug remaining following 5 minutes storage at various temperature  
  – crystalline drug substance (A), and physical mixture of drug and polymer at  





































2.3.4 Drug-polymer miscibility  
To produce stable amorphous molecular dispersions, the miscibility between drug 
and polymer(s) must be understood. Hansen solubility parameters and Flory-Huggins 
interaction parameters were used to model the phase diagrams of binary mixtures.   
2.3.5 Hansen solubility parameter 
The miscibility criteria suggested by Greenhalgh et al. (1999) [41] categorizes the 
level of miscibility between two compounds, based on the Dδ, into three groups. If the Δδ 
< 2 MPa1/2, the drug and carrier are likely to be miscible and produce a glass solution when 
molten. If the Δδ < 7 MPa1/2, the drug and polymer are also likely to be miscible and 
possibly form a glass solution in a liquid state. Whereas the Δδ > 10 MPa1/2 show some 
signs of immiscibility and may not form the glass solution. These solubility parameters 
were utilized as a tool for carrier selection.  
The solubility parameters of ABZ, Kollidon® VA 64, Soluplus® and Eudragit®   
E PO were calculated of 25.96, 23.52, 22.19, and 19.60 MPa1/2, respectively and the Dδ 
between ABZ and these three polymers were 2.44, 3.77 and 6.36 MPa1/2, respectively, 
which were less than 7 MPa1/2. ABZ is likely to be more miscible with Kollidon® VA 64 
than the other two polymers at 25°C.  
2.3.6 Flory-Huggins Theory and Gibbs free energy of mixing  
The Flory-Huggins theory is used to evaluate thermodynamic miscibility of a 




between free energy of mixing versus drug ratio are shown in Figure 2.5A-C. The positive 
energy of mixing indicates that the energy of the mixed state is greater than that of the 
phase-separated state, which results in the drug and polymer spontaneously separating into 
two phases in order to reduce the free energy. On the other hand, the negative energy of 
mixing demonstrates that the energy of the mixed state is less than that of the phase-
separation state, which leads to the promotion of mixing and results in homogeneous 
mixtures of drugs and polymers [16,42]. It is apparent that the free energy of mixing is 
negative and convexed at the elevated temperatures of 150°C and above for the binary 
systems of ABZ-Kollidon® VA 64 and ABZ-Soluplus®, and 100°C and above for the 
ABZ-Eudragit® E PO system. Therefore, at these temperatures, the mixtures are 










Figure 2.5:  Gibbs free energy diagram of the mixture of ABZ–Kollidon® VA 64 (A), 
Soluplus® (B), and Eudragit® E PO (C)  
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Figure 5.  Gibbs free energy diagram of the mixture of ABZ–Kollidon® VA 64 (a),    
  














































































2.3.7 Temperature – Composition phase diagram  
Phase diagrams are potentially useful for the prediction of the physical stability of 
solid dispersions [16]. Figure 2.6 shows the phase diagrams of three drug-polymer 
mixtures, the appearance of extrudates and the PXRD patterns. The phase diagrams 
demonstrate the stable, metastable and unstable zones of the systems as a function of 
temperature. Drug-polymer miscibility and drug-polymer solubility are indicated by 
spinodal and binodal curves, respectively [43]. These two curves and the Tg also imply the 
viscosity change of the systems which are related to their molecular mobility [39]. The 
mixtures under the Tg curve have low molecular mobility. In contrast, above the Tg curve, 
molecular mobility of the system is high which results in the increasing of molecular 
motion and demixing of the systems. The systems, however, may remain crystal-free over 
pharmaceutically relevant timescales [14,16,42,43].  
The amorphous solid dispersions are typically transparent, and the degree of 
crystallinity increases the opacity of the systems [44]. The solid dispersions of ABZ-
Kollidon® VA 64 and ABZ-Soluplus® at 10% drug loading, which falls in the metastable 
zone, were clear and transparent. While the formulations with higher drug content (20% 
and 30%) were more opaque. At ambient temperature, the 20% ABZ in the Soluplus® 
matrix is the point that is closest to the boundary between the metastable and the two-phase 
unstable zone, and the extrudate was not as clear as the one containing 10% ABZ. This 
observation was confirmed by the PXRD results (peaks at 2q = 17.5°, 22.5°, 24.5° and 




low drug levels (1% and 5%) and also became more opaque when the drug loadings 
increased (10% and 20%). The observation was again corroborated by PXRD (crystalline 
ABZ peak at 2q = 24.5°). The discharged extrudates were opaque at the outlet. This 
suggested that the drug in polymer dissolution process simply takes longer at the higher 
drug loadings and was incomplete. Therefore, Flory-Huggins modeling indicated that the 
amorphous state of ABZ in each of the polymer systems would exist at low drug loadings. 
The results from this study prove that phase diagrams are a powerful tool to model the 
phase separation of binary mixtures. Interestingly, even though a majority of drug degraded 
during processing (e.g. 71.4% of ABZ degraded from the ABZ-Kollidon® VA 64 (20:80) 
formulation), the phase diagram was still valid. The solubility parameter of the degradant, 
which was ABZ impurity A, was calculated as 26.87 MPa1/2. The value is very similar to 
the drug itself (25.96 MPa1/2), therefore this supports that the results are still relevant 






Figure 2.6:  Phase diagrams of ABZ–polymer binary systems and the appearance of the 
extrudates at different drug fractions (ABZ); ABZ–Kollidon® VA 64 (A), 
ABZ–Soluplus® (B), and ABZ–Eudragit® E PO (C) at extrusion temperature 








































Figure 6. Phase diagrams of ABZ–polymer binary systems and the appearance of the 
extrudates at different drug fractions (ABZ); ABZ–Kollidon® VA 64 (a), ABZ–
Soluplus® (b), and ABZ–Eudragit® E PO (c) at extrusion temperature of 140°C, 









































































2.3.8 Hot melt extrusion 
Based on the preformulation studies, particularly the thermal stability profile and 
phase diagram, we hypothesize that amorphous solid dispersions of ABZ could be prepared 
by thermal processing. Table 2.2 presents the results of the extrusion products including 
the extent of ABZ remaining, PXRD, and physical appearance of the extrudates. The 
thermal degradation profiles of ABZ-Kollidon® VA 64 mixtures show that the onset of the 
degradation occurs at 140°C. In addition, preliminary studies in which the barrel 
temperature was below 120°C did not convert crystalline ABZ to the amorphous state (data 
not shown). Thus, formulations 1-3 were run at 120°C with different screw speeds and 
unexpectedly more than 90% of ABZ was degraded during the extrusion process. The 
increase in screw speed induces higher mechanical shear force, which increases chemical 
degradation [45,46]. The hydrolysis degradation product, ABZ impurity A, was detected 
by HPLC and LC/MS, and methanol, a by–product of ABZ degradation, vaporized and 
created bubbles in the extrudates. Visual observations supported the chemical assays. 
Transparency of the extrudates and foam formation during the extrusion process indicated 
the presence of crystallinity and decomposition of ABZ. A recent study of ABZ solid 
dispersions produced by HME [12] also observed bubbles in the extrudates. Their 
dissolution results, under sink conditions measured by UV spectrophotometry at 250 nm, 
showed only about 70% completion. The authors speculate on why, however, they have 
not proven this phenomenon. Our results revealed that ABZ is sensitive to both thermal 




(RTD) of this study (13 min) also induced ABZ degradation. The RTD is a critical factor 
that significantly affects the chemical stability of thermal labile compounds like ABZ. 
Impurity formation, as a result of thermal processing caused by RTD at elevated 
temperatures, has been reported [21]. Therefore, the long residence time and high shear in 
this present work seriously strengthened the thermal degradation of ABZ. 
Ethanol was introduced to the extrusion process to reduce the processing 
temperature. In a comparison between formulations 3 and 6, the percent drug remaining 
increased about 11 fold (from 2.63% to 28.17%). However, the percent drug remaining 
was still unacceptably low. The use of a lower screw speed of 150 rpm with ethanol 
injection in formulations 4 and 5 still did not sufficiently reduce drug degradation. 
Formulations 7 and 8 were then processed at lower barrel temperatures (110 °C and 100 
°C). Unfortunately, at temperature of 100 °C with solvent assistance did not produce ABZ 
amorphous solid dispersion. Therefore, HME is not a suitable process for preparing ABZ 
amorphous solid dispersions due to significant chemical degradation from heat and shear 




Formulation %ABZ remaining XRD Physical Appearance 
Blend 100.00     
1 9.49 Amorphous Clear glass extrudate with bubbles 
2 4.45 Amorphous Clear glass extrudate with bubbles 
3 2.63 Amorphous Clear glass extrudate with bubbles 
4 26.54 Amorphous Clear glass extrudate with bubbles 
5 35.46 Amorphous Clear glass extrudate with bubbles 
6 28.17 Amorphous Clear glass extrudate with bubbles 
7 28.95 Amorphous Translucent extrudate with bubbles 
8 56.62 Crystalline  Opaque extrudate with bubbles 
Table 2.2: Drug content, crystallinity and physical appearance of hot-melt extruded ABZ-Kollidon® VA 64 extrudate
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2.3.9 Spray-dried formulation 
Spray drying is another prevalent technique to produce amorphous solid dispersions 
of ABZ in a polymer matrix. The acids used to prepare ABZ salts were also added to the 
spray dried formulations. Without assistance of the acids, the ABZ-polymer solutions for 
spray drying cannot be obtained. The results indicate that there was no degradation product 
detected in all spray-dried formulations. Spray drying also utilizes high temperatures 
during processing, the liquid droplets are typically in contact with the hot air inlet in the 
drying chamber for short periods of time [47]. In addition, the temperature of the droplets 
remained low due to the high evaporation rate of the solvent. The temperature of the 
products exiting the dryer was slightly less than the outlet air temperature [47]. The outlet 
temperature of all formulations was in the range of 55-65 °C. When the droplets dried in 
the chamber, the moisture content and air temperature were reduced, which resulted in the 
temperature of the particles not markedly increasing. As previously reported, a spray dryer 
with a co-current configuration is appropriate for thermally sensitive drugs due to the short 
evaporation time which results in less thermal degradation of the products [48,49]. 
Therefore, spray drying was better than HME as it avoided thermal degradation of ABZ. 
2.3.10 Characterization of spray-dried formulations 
2.3.10.1 PXRD  
PXRD reportedly quantifies to a limit of about 5% or less crystallinity in solid 
dispersions, depending on the size and shape of the crystals [50,51]. The broad halo 
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scattering profiles of the spray-dried ABZ in Kollidon® VA 64 and Soluplus® indicated 
the amorphous morphology of the spray-dried matrices. Interestingly, partially crystalline 
ABZ remained in the spray-dried ABZ-Eudragit® E PO formulation (peaks at 2q = 7.5°, 
17.5°, and 24.5°).  
2.3.10.2 DSC 
DSC determines the extent of mixing in polymer systems [52]. If an amorphous 
drug is molecularly dispersed in the polymer matrix, the solid dispersion system exhibits a 
single Tg [53]. The calculated Tg value of each of the molecular dispersions is between 
that of the pure amorphous drug and pure polymer. A single Tg for each spray-dried ABZ 
formulation was detected. However, a small melting peak at about 210°C was still observed 
in the ABZ-Eudragit® E PO sample (Figure 2.7A). The predicted and experimental Tg of 
the spray-dried ABZ-Kollidon® VA 64, ABZ-Soluplus®, and ABZ-Eudragit® E PO were 
91.3°C/91.1°C, 67.3°C/70.0°C, and 49.8°C/55.8°C, respectively (Figure 2.7B). The 
prediction of Tg was very accurate for the ABZ-Kollidon® VA 64 samples. It was difficult 
to notice the multiple Tg(s) from the ABZ-Eudragit® E PO formulation since their Tg(s) 
are close to each other (Tg pure ABZ is 57°C and Tg of Eudragit® E PO is 48°C). However, 
the large difference (about 6°C) between the predicted and experimental Tg of ABZ-
Eudragit® E PO might imply the lack of homogeneity of the system. Hence, the higher 
experimental Tg of the ABZ-Eudragit® E PO formulation than the predicted Tg was 
attributed to partially crystalline ABZ in the mixture.  
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2.3.10.3 SEM images 
The SEM image has a high sensitivity and is able to detect a very low crystalline 
level (1% or less) of the drug in spray-dried formulations [14]. Figure 2.8 shows the 
morphology and size of bulk ABZ, pure Kollidon® VA 64, physical mixtures, and the 
spray-dried products. Overall, the spray-dried formulations appeared in a good spherical 
shape without any collapse of skin. The SEM images revealed a reduction in the particle 
size of the solid dispersions from the physical mixtures (for example, Figure 2.8D and C). 
Interestingly, the irregular-shaped particles of crystalline ABZ were observed in the ABZ-
Eudragit® E PO formulation. This confirmed the XRD results that the ABZ-Eudragit® E 
PO formulation contained fractions of crystalline drug. 
2.3.10.4 Particle size distribution (PSD) of spray-dried formulations 
The upper diameter of the smallest 90%, x(90%), of bulk ABZ, spray-dried ABZ-
Kollidon® VA 64, ABZ-Soluplus® and ABZ-Eudragit® E PO were 14.75, 15.81, 14.82 
and 10.58, respectively. The Eudragit® E PO formulation gave the smallest particle size 
while the particle size of the other spray-dried formulations was not significantly different 
from the crystalline drug. The poor water solubility of the bulk ABZ was attributed to low 




Figure 2.7:  DSC thermograms of bulk ABZ and spray dried ABZ-polymer systems from 
a plot of heat flow (W/g) versus temperature (°C) (A), and glass transition 
temperatures (Tg(s)) of bulk ABZ and spray dried ABZ-polymer systems 







































Figure 7. DSC thermograms of bulk ABZ and spray dried ABZ-polymer systems from a plot 
of heat flow (W/g) versus temperature (°C) (a), and glass transition temperatures 
(Tg(s)) of bulk ABZ and spray dried ABZ-polymer systems from a plot of reverse 













































Figure 2.8:  SEM images of bulk ABZ (A), Kollidon® VA 64 (B), physical mixture of 
ABZ and Kollidon® VA 64 (C), spray-dried formulations (ABZ–polymer 
20:80) as follows; ABZ–Kollidon® VA 64 (D), ABZ-Soluplus® (E), and 
ABZ–Eudragit® E PO (F), magnification of 2,000X for (A)-(C) and 10,000X 














2.3.11 Recrystallization of ABZ in spray-dried formulations 
In reference to the crystalline ABZ detected in the spray-dried ABZ-Eudragit® E 
PO, the recrystallization of ABZ was discussed. Crystallization of an amorphous material 
depends mostly on molecular mobility [40,53] and the molecular mobility also relies on 
both thermodynamic and kinetic factors [54,55]. The Dδ of ABZ and polymers, which 
determine the solubility and miscibility of a drug in polymer matrices, were ranked. The 
spray-dried ABZ-Eudragit® E PO formulation has the highest difference value and was 
observed in the recrystallization. In the phase diagrams (Figure 2.6), within the 
pharmaceutically relevant temperature range (0-50°C), the dispersions of amorphous ABZ 
in Kollidon® VA 64 and Soluplus® at 20% drug loading are in the metastable region, 
where the drug achieved a supersaturated state in the polymer matrices. If a formulation in 
this metastable zone is appropriately engineered, the kinetic barrier will be high enough to 
prevent phase separation. The ABZ-Eudragit® E PO (20:80) system at temperatures below 
30°C clearly falls within the two-phase unstable zone, where the drug is supersaturated but 
immiscible with the polymer carrier. The high driving force of the drug toward 
recrystallization at this supersaturated state resulted in the increase of crystalline drug 
particles in the polymeric dispersions [16].  
From the kinetic perspective, molecular mobility of the amorphous material is high 
at the area above the Tg curve. The differences between the Tg of the spray-dried 
formulations (ABZ-Kollidon® VA 64, ABZ-Soluplus®, and ABZ-Eudragit® E PO) and 
room temperature (25°C) were 66, 45 and 31°C, respectively. A rule of thumb for 
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determining the storage temperature of the amorphous solid dispersions is that the physical 
stability of the amorphous dispersions is considered to be stable if the Tg of the system is 
50°C above the storage temperature [56]. The amorphous material exhibits substantial 
molecular mobility at temperatures up to 50°C below the Tg of the system, which initiates 
the recrystallization of the amorphous drug in the ABZ-Eudragit® E PO system.   
The ratio of the ABZ melting point to the Tg of the ABZ-Eudragit® E PO was 
highest. This melting point to Tg ratio indicates the ability of glass formation [57] and 
relates to the physical stability of the drug in solid dispersions [14]. Harmon et al. (2009) 
[54] reported that ‘the higher this ratio, the greater is the risk of crystallization.’ Drugs with 
high melting temperatures are more likely to recrystallize since the melting temperature 
exhibits the crystal lattice energy and can be a tool to indicate the thermodynamic driving 
force toward recrystallization. On the other hand, Tg can reflect molecular mobility of the 
dispersion system. Material with low Tg has a high risk of recrystallization at room 
temperature due to its high molecular mobility [54].  
2.3.12 ABZ salts 
In brief, the ABZ salts (ABZ mesylate, sulfate and hydrochloride) were prepared 
and agreed to those reported by Paulekuhn et al. (2013) [10] (data not presented). In 
addition, there was no degradation products of ABZ detected. 
 
 69 
2.3.13 Non-sink dissolution  
 
The non-sink dissolution was conducted to evaluate the in vitro dissolution 
performance of the solid dispersions. ABZ exhibits significantly higher solubility in the 
ionized form in acidic conditions. Hence, all dissolution studies were demonstrated in USP 
simulated gastric fluid. Results of the dissolution analysis are presented in Figure 2.9A-C, 
and the area under the dissolution curves (AUDC) values were summarized in Table 2.3.  
Figure 2.9A shows the non-sink dissolution profiles of the free base and salts of 
ABZ. The mesylate salt showed immediate dissolution within 5 min and exhibited the 
highest dissolution enhancement of about 5-fold as compared to the free base form. 
Enhanced wettability of the mesylate salt contributed to this dissolution enhancement [10]. 
Nonetheless, the extent of ABZ dissolved was decreased over time because the salt was 
not able to maintain the supersaturated state. Referring to the study by Paulekuhn et al. 
(2013), ABZ mesylate, sulfate and hydrochloride salts were the anhydrate, hydrate and 
hemihydrate, respectively [10]. Therefore, the slower rate of the sulfate salt may be 
attributed to its hydrate form [58]. ABZ hydrochloride exhibited the lowest rate and extent 
of dissolution in comparison to the other two salts due to the common ion effect of the 
chloride ion [10,59]. Paulekuhn et al. (2013) also suggested that the formulation 
development of ABZ should be considered since ABZ salts did not have an effect on the 
microenvironmental pH for a long period of time in the media used and may not achieve 
the expected dissolution result in the patient’s stomach [10].  
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To maintain the supersaturation of the drug, spray-dried formulations of ABZ and 
methanesulfonic acid with various types of polymers were prepared. Figure 2.9B shows 
that all three polymers (Kollidon® VA 64, Soluplus® and Eudragit® EPO) were capable 
of promoting drug release and prolonging the drug supersaturation in the acidic medium. 
The spray-dried formulation with Kollidon® VA 64 matrix proved to be superior to the 
other two polymers. The AUDC of the Kollidon® VA 64 formulation was 2- and 3-fold 
higher than the Soluplus® and the Eudragit® E PO formulations, respectively. Since the 
drug still partially existed in a crystalline state in the spray-dried ABZ-Eudragit® E PO 
dispersion, this formulation exhibited the lowest dissolution rate and extent compared to 
the complete amorphous dispersions.  
There are a few possible explanations for the slower dissolution rate and lower drug 
release of the spray-dried ABZ-Soluplus® than the Kollidon® formulation. First, as 
discussed earlier, Δδ between ABZ and Soluplus® is slightly greater than ABZ and 
Kollidon® VA 64, therefore the miscibility of ABZ with Soluplus® is likely to be poorer 
than with the Kollidon® VA 64. Second, the Tg of the spray-dried ABZ-Soluplus® was 
about 20°C below the ABZ-Kollidon® VA 64. In the presence of the dissolution media, 
amorphous solid dispersion systems spontaneously absorbed water from the surroundings, 
and water usually acted as a potent plasticizer of the system. The Tg of the system rapidly 
decreased from the dry state after absorption of water into the system. Thus, when the Tg 
of the system decreases, the molecular mobility of the drug molecule in the polymer matrix 
is likely increased, leading to recrystallization [60]. Lastly, slower ABZ diffusion and 
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dissolution from the solid dispersion of the Soluplus® formulation was attributed to the 
swelling effect of Soluplus®, which should occur in the patients as well [61].  
As spray drying is a particle engineering technique, the PSD of these formulations 
was taken into account. The particle size of the ABZ-Eudragit® E PO was the smallest; 
however, in contrast, the dissolution performance was slowest among these three 
formulations. There was no significant difference in the particle size between ABZ-
Kollidon® VA 64 and ABZ-Soluplus® spray-dried dispersions, while the dissolution 
results were substantially different. Thus, it can be concluded that the particle size of the 
spray-dried formulations did not have an effect on the dissolution, whereas the type of 
polymer was played an important role in the improvement of ABZ dissolution.   
Since the spray-dried ABZ mesylate formulation with Kollidon® VA 64 exhibited 
the greatest dissolution performance (both rate and extent), Kollidon® VA 64 was selected 
for the acid salt study. Figure 2.9C shows the dissolution profiles of the spray-dried 
formulations with acids. Overall, the spray-dried formulations showed improved non-sink 
dissolution compare to the ABZ free base, salts and the physical mixture of ABZ and 
Kollidon® VA 64. The formulation containing methanesulfonic acid exhibited the best 
performance, that was about 8-, 1.6- and 5.6-fold (AUDC) greater than the bulk material, 
ABZ mesylate salt, and physical mixture of ABZ-Kollidon® VA 64 (20:80), respectively. 
This can be attributed to a combination of the mesylate salt and polymer used. Again, the 
lower dissolution improvement of spray-dried ABZ hydrochloride:Kollidon® VA 64 as 
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compared to the mesylate formulation was attributed to the common ion effect of the 
chloride ion.  
 
(A) 
         
Figure 2.9:  (A) Non-sink dissolution of bulk ABZ and ABZ salts in 100 mL USP 
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Figure 2.9:  (B) Non-sink dissolution of bulk ABZ and spray-dried ABZ 
mesylate:polymer (20:80) in 100 mL USP simulated gastric fluid (without 
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Figure 2.9: (C) Non-sink dissolution of bulk ABZ, physical mixture of ABZ:Kollidon® 
VA 64 (20:80), and spray-dried ABZ salt:Kollidon® VA 64 (20:80) in 100 
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ABZ	hydrochloride:	 Kollidon	 VA	64	(20:80)	(Spray-dried) ABZ:	Kollidon	 VA	64	(20:80)	(Physical	mixture)
Bulk	ABZ Equilibrium	 solubility
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Formulation   AUDC (mg.min) 
Bulk ABZ 6,376±319 
ABZ hydrochloride salt 14,621±1,847 
ABZ sulfate salt 17,175±298 
ABZ mesylate salt 32,161±328 
Physical mixture ABZ:Kollidon® VA 64 (20:80) 9109±219 
Spray-dried ABZ hydrochloride:Kollidon® VA 64 (20:80)  29,665±726 
Spray-dried ABZ sulfate:Kollidon® VA 64 (20:80) 29,127±656 
Spray-dried ABZ mesylate:Kollidon® VA 64 (20:80) 51,303±4,937 
Spray-dried ABZ mesylate:Soluplus® (20:80) 25,529±814 
Spray-dried ABZ mesylate:Eudragit® E PO (20:80) 11,749±853 
 
Table 2.3:  Summary of supersaturation values of the area under the dissolution curve 
(AUDC) for the USP simulated gastric fluid (without pepsin) at 37°C 
 
2.3.14 Long term stability study of spray-dried formulations 
As the spray-dried ABZ mesylate:Kollidon® VA 64 formulation showed the best 
performance, this formulation was selected for the long term stability study. The drug still 
remained in the sample after 6-months and 1-year storage as 99.24% and 96.87%, 
respectively. The two degradation products (ABZSX and ABZ impurity A) were detected 
at a very low level (less than 2%) after 1 year (Table 2.4). There was no recrystallization 
of ABZ observed in the X-ray patterns. This great stability data can be used as a guideline 
for designing a package for the product, and recommended storage conditions.   
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Duration of storage  ABZ 
(% label claim) 
ABZ sulfoxide (Oxidation) 
(% of ABZ) 
ABZ Imp A (Hydrolysis) 
(% of ABZ) 
Initial 100.00 - - 
6-month storage 99.24 0.34 0.42 
1-year storage 96.87 1.47 1.67 
 
Table 2.4:  Assay and impurity content of ABZ mesylate-Kollidon® VA 64 formulation 




ABZ solid dispersions prepared by spray drying were amorphous and showed enhanced 
dissolution and shelf-stability, whereas those made by hot melt extrusion were degraded 
by heat and shear stress. The dissolution enhancement is attributed to the effects of salt 
formation and hydrophilic polymer used in the spray-dried formulation. Thermodynamic 
models of drug-polymer systems based on the Flory-Huggins theory provided useful 
information of the solubility and miscibility between the drug and polymer, which helps 
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Chapter 3:  Optimization of Formulation for Novel Inhaled Anti-




A caveolin-1 scaffolding domain, CSP7, is a newly developed peptide for the 
treatment of idiopathic pulmonary fibrosis.  To optimize the formulation for further use we 
have obtained, characterized and compared a number of lyophilized formulations of CSP7 
with DPBS and in combination with excipients (mannitol and lactose at molar ratios 1:5, 
70 and 140). CSP7 was stable (>95%) in solution at 5 and 25°C for up to 48 hours and 
tolerated at least 5 freeze/thaw cycles. Lyophilized cakes of CSP7 with excipients were 
stable (>96%) for up to 4 weeks at room temperature (RT), and retained more than 98% of 
the CSP7 in the solution at 8 hours after reconstitution at RT.  The lyophilized CSP7 
formulations were stable for up to 10 months at 5°C protected from moisture. Exposure of 
the lyophilized cakes of CSP7 to 75% relative humidity (RH) resulted in an increase in the 
absorbed moisture, promoted crystallization of the excipients and induced reversible 
formation of CSP7 aggregates. Increased molar ratio of mannitol slightly affected 
formation of the aggregates. In contrast, lactose significantly decreased (up to 20-times) 
aggregate formation with apparent saturation at the molar ratio of 1:70.  The possible 
mechanisms of stabilization of CSP7 in solid state by lactose include physical state of the 
bulking agent and the interactions between lactose and CSP7 (e.g., formation of a Schiff 
base with the N-terminal amino group of CSP7). Finally, CSP7 exhibited excellent stability 
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during nebulization of formulations containing mannitol or lactose.  Thus, a combination 
of CSP7 and lactose (1:70 molar ratio) exhibited the greatest stability and is considered the 
lead formulation for future testing in vivo.  
3.1 INTRODUCTION 
Idiopathic Pulmonary Fibrosis (IPF) is a serious, chronic and progressive interstitial 
lung disease. By definition, IPF is a build-up of scar tissue in the lung parenchyma from 
unknown origins (1). This condition often occurs in elderly male smokers or ex-smokers 
and results in restrictive lung dysfunction (2–4). In the general population, prevalence 
estimates for IPF have varied from 14 to 43 cases per 100,000 people per year and it is 
known to be increasing (1). Median survival is about three years after the condition is 
diagnosed (5) and mortality usually results from respiratory failure (6). While not well-
appreciated, survival from IPF is actually lower than many malignancies (4). Current 
treatments for IPF include nintedanib (7), pirfenedone (8), oxygen therapy (1), and in 
advanced cases, lung transplantation (9).  Unfortunately, none of these interventions are 
curative and lung transplantation is invasive, expensive and carries its own co-morbidities. 
Recently identified pharmacotherapy can slow the progression of disease indicating 
that better treatment is possible. A caveolin-1 scaffolding domain 7-mer peptide (CSP7), 
FTTFTVT, is being developed by Lung Therapeutics Inc. for testing for treatment of 
patients with IPF. CSP7 can inhibit tumor suppressor protein (p53), alveolar epithelial cell 
(AEC) apoptosis. In AEC, when expression of p53 increases, AEC apoptosis is augmented. 
Apoptotic AECs are replaced by activated fibroblasts or fibrotic lung fibroblasts (fLFs) 
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which proliferate, resist apoptosis and deposit matrix proteins (10). CSP7 has an effect on 
both pathways to stop or reverse development of PF. These effects of CSP7 result in the 
prevention of PF development in mice after bleomycin (BLM)-induced lung injury (11–
15). Therefore, CSP7 has emerged as a new and promising compound for airway delivery 
via nebulization to treat IPF. If this treatment is successful in future clinical trial testing, it 
may benefit thousands of patients suffering from IPF in the US and worldwide. Thus, a 
stable CSP7 formulation prepared by lyophilization and a reconstituted solution delivered 
to the lung using a nebulizer was initially investigated for preclinical assessment and for 
subsequent clinical trial utilization. 
Lyophilization is used to enhance the stability of peptides since the molecular 
mobility and reactivity of the peptides in the solid state are reduced (16). However, it is 
known that residual or absorbed moisture can induce physical and chemical instability of 
peptide and protein drugs in the lyophilized state, such as aggregation and degradation (17). 
Aggregation often leads to unfavorable outcomes (e.g., reduction of biological activity, 
solubility or enhancement of immunogenicity) (18,19). Residual moisture content of the 
lyophilized products may depend on the bulking agent(s) used in formulations (20–22). A 
number of publications document that the physical states of the bulking agents have a 
strong impact on stabilization of the lyophilized products (23–27). Mannitol and lactose 
are the most commonly and widely used in lyophilized protein/peptide formulations (27–
29). Typically mannitol, a non-reducing sugar, provides a robust cake structure, which 
undergoes micro-collapse; however, its crystallization behavior leads to an unexpected 
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protective effect (24,25,29,30). On the other hand, lactose, a disaccharide reducing sugar, 
usually remains in an amorphous state during the freeze-drying process (31,32).  
Biopharmaceuticals for treatment of pulmonary disease can be directly delivered to 
the lungs to minimize their systemic exposure and to increase their efficiency and safety 
(33,34). Nebulization is used for airway delivery of protein and peptide drugs. However, 
during nebulization, thermolabile proteins can be partially denatured leading to loss of its 
activity, formation of aggregates, which may lead to an unwanted outcomes like increasing 
in immunogenicity (35). These effects result from stress on proteins in the droplets and 
bulk reservoir liquid. Hence, the evaluation of the effects of nebulization process on 
activity and stability of therapeutics is critical to the development of novel protein 
formulations to use in preclinical and clinical trials. Currently used nebulizers are 
categorized by their mechanism of nebulization such as jet, ultrasonic and vibrating mesh 
(or membrane) nebulizers (35). To address/minimize potential degradation and inactivation 
of biologics, vibrating mesh nebulizers have been recommended to aerosolize protein and 
peptide formulations (36,37). These devices gently generate the aerosol plume (38,39) with 
low shear force (40). Thus, vibrating mesh nebulizers are considered suitable/optimal 
method devices for pulmonary protein/peptide delivery. 
The present study was focused on evaluation of stability of CSP7 and finding an 
optimal formulation for further in vivo clinical studies. The physical and chemical stability 
of CSP7 in both liquid and lyophilized states, and the effect of nebulization on stability of 
CSP7 solutions were evaluated. Stability assessments include characterization of moisture-
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induced aggregates using various techniques such as high performance liquid 
chromatography (HPLC), liquid chromatography/mass spectroscopy (LC/MS), and 
matrix-assisted laser desorption/ionization time-of-flight mass spectrometer (MALDI-
TOF MS). In addition, effects of moisture-induced crystallization of bulking agents are 
also reported. 
3.2 MATERIALS AND METHODS 
3.2.1 Materials 
 The CSP7 (purity > 95%), was kindly provided by Lung Therapeutics, Inc. 
(Austin, TX). Lactose monohydrate was purchased from Foremost Farms (Baraboo, WI). 
Dulbecco’s phosphate buffered saline (DPBS) without calcium or magnesium was 
purchased from Lonza (Walkersville, MD). Mannitol, ammonium hydroxide solution 
(28%w/w in water) ultrapure water, HPLC grade solvents were purchased from Fisher 
Scientific (Fair Lawn, NJ). All other chemicals utilized in this study were of ACS grade.  
3.2.2 Chromatographic analysis 
Samples were chemically analyzed with a Dionex 3000 HPLC system (Thermo 
Fisher Scientific, Fair Lawn, NJ) with a wavelength of 220 nm. CSP7 was eluted by 
Phenomenex® Luna 5µ  C18(2) 100 Å, 150 mm x 4.6 mm (Phenomenex®, Torrace, CA) 
column at a flow rate of 1.0 mL/min. Two mobile phases were A (0.1% trifluoroacetic acid 
in water) and B (0.09% trifluoroacetic acid in a mixture of 20:80, water and acetonitrile). 
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The HPLC gradient consisted of 25-35% mobile phase B in 20 min and was run at ambient 
temperature. 20 µL of each sample was injected onto the column and chromatograms were 
acquired at the detection wavelength of 220 nm. Standard curve of the CSP7 
(concentrations of 0.1-1 mg/mL) were prepared. Duplicate determinations were made for 
each sample. LC/MS was used for to confirm identity.  
3.2.3   Preformulation studies 
3.2.3.1 Aggregation and chemical stability of peptide solution 
Aggregation and chemical stability of the peptide solution was studied prior to 
developing the lyophilized formulation. The solutions of CSP7 dissolved in DPBS with 
minimal amount of ammonium hydroxide solution (28%w/w in water) (concentration 0.5 
mg/mL) were prepared to test the effects of agitation, freeze-thaw cycles and storage 
temperature as follows: 
3.2.3.2 Effect of agitation 
The solutions of CSP7 were shaken on an orbital shaker at 200 RPM at 5°C and 
25°C. The samples were collected at 0.5, 1, 3, 6, 12 and 24 hours and analyzed by HPLC 
as described in section 3.2.2.  
3.2.3.3 Effect of multiple freeze-thaw cycles 
Freeze-thaw cycles were studied at -20°C and -80°C. The peptide solutions were 
frozen at each temperature for 1 hour and then thawed at room temperature for 1 hour. The 
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freeze-thaw cycle was repeated for 5 cycles and the samples were collected after each cycle 
and analyzed by HPLC as described in section 3.2.2.  
3.2.3.4 Effect of storage temperature 
CSP7 solutions were kept at -80°C, -20°C, 5°C and room temperature (about 25°C). 
Samples were collected after 24 and 48 hours and analyzed by HPLC as described in 
section 3.2.2. 
3.2.4   Formulation preparation  
Solutions of CSP7 were prepared by dissolving the peptide (concentration of 0.5 
mg/mL) and bulking agents (mannitol or lactose) in the following CSP7:excipient molar 
ratios of 1:5, 1:70 and 1:140 in DPBS with pH adjusted to 8.0 by ammonium hydroxide 
solution (28% w/w). Resulting solutions were filtered through a 0.2 µm PES filter 
(Celltreat Scientific Products, Shirley, MA). Aliquots of 2 mL of the solution were filled 
into 5 mL borosilicate glass vials. Rubber stoppers were placed on top of the vials prior to 
loading on the lyophilizer. Samples were lyophilized using VirTis BenchTop lyophilizer 
(Gardiner, NY). Lyophilized cycle parameters are as presented in Table 4.1 (Chapter 4). 
Primary drying time may vary depending on the number or volume of samples. At the 
completion of the cycle, nitrogen was introduced into the chamber. Vials were sealed with 
rubber stoppers and aluminum closure, and kept in a desiccator with desiccant at 5°C until 
tested.  
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3.2.5 Chemical stability of peptide 
3.2.5.1 Chemical stability of peptide in reconstituted solution  
 The lyophilized formulation of CSP7-mannitol (1:140) cakes was 
reconstituted to 0.5 mg/mL and kept at 5°C and 25°C. The samples were collected in 
duplicate at 0.5, 1, 2, 3, 6, and 8 hours. The aggregation was observed and chemical 
stability of the peptide was then determined by HPLC as described in section 3.2.2. 
3.2.5.2 Chemical Stability of peptide in lyophilized state  
Vials of lyophilized CSP7-mannitol (1:140) cakes were stored at 5°C and 25°C and 
sampled in duplicate after 1, 2, and 4 weeks. The lyophilized cakes were reconstituted (0.5 
mg/mL) and the solutions were then investigated for aggregation and chemical stability of 
the peptide by visually observation, HPLC and LCMS. Residual moisture content, 
osmolality, reconstitution time and pH of the samples were also monitored at each time 
point.  
3.2.6 Karl Fischer Titration   
Measurement of moisture content was demonstrated by Karl Fischer titration using 
an Aquatest 2000 moisture analyzer (Photovolt Instruments, Minneapolis, MN). 
Anhydrous methanol (1 mL) was added to the pre-weighed sealed sample vial by syringe 
through the rubber stopper and mixed using vortex mixer. Sample aliquots were withdrawn 
and transferred to the Karl Fischer vessel. Moisture content of 1mL anhydrous methanol 
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was also determined and subtracted from the moisture content of samples. Dry, clean empty 
vial was weighed. Percentage of moisture content was calculated and compared between 
freshly prepared lyophilized cakes and the samples after exposure to 75% RH. Moisture 
analysis was performed in triplicate for each of the samples. 
3.2.7 Osmolality measurements 
Osmolality of the reconstituted solutions of CSP7-mannitol and lactose (1:140 and 
1:70) were performed on a 5004 Micro-osmetteTM High Sensitivity Osmometer (Precision 
Systems Inc. Natick, MA) with 50 µL sample volume. The equipment was calibrated using 
osmometry standard solutions of 100 and 500 mOsm/kg H2O (Precision Systems Inc. 
Natick, MA) before measurement. The osmolality of the reconstituted CSP7 in sterile water 
for injection (SWI), DBPS and solutions of mannitol (or lactose) in SWI were measured in 
triplicate. 
3.2.8 Measurement of reconstitution time 
 Reconstitution time of lyophilized cake was measured by injecting 2.0 mL 
of SWI into the sample vial. The vial was gently swirled. Two mL of SWI was used as 
control sample. Clarity of the reconstituted solution was compared with the control every 
5 seconds and the reconstitution time was recorded when visual clarity was observed. 
Samples were tested in duplicate.  
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3.2.9 Moisture-induced aggregation and quantitation of CSP7 aggregates 
Lyophilized formulations of CSP7 with both sugars (molar ratios of 1:5, 1:70 and 
1:140) were initially prepared. The sample vials were then opened and placed in a 
desiccator containing an aqueous saturated sodium chloride solution at constant relative 
humidity (75% relative humidity (RH)). The desiccator was stored at room temperature for 
12 hours. After incubation, two vials of exposed sample powders were resealed before 
testing moisture content by Karl Fisher titration. The other four vials were reconstituted 
with SWI to a concentration of 0.5 mg/mL, then shaken on an orbital shaker (Lab-Line 
Instruments, Inc., Melrose Park, IL) at 100 rpm in a cold room (5°C). After 2 hours of 
shaking, two vials of the aggregated samples were centrifuged at 12,000 rpm for 15 min in 
the microcentrifuge (model Microfuge 18, Beckman Coulter, Brea, CA). The clear 
supernatant and aggregate samples were collected. The separated aggregates were re-
dissolved in 2 mL of DPBS with ammonium hydroxide solution (28%w/w in water) to 
render clear solutions (pH 8). Controls were composed of reconstituted solutions of each 
freshly prepared sample. All clear sample solutions were analyzed by HPLC and LC/MS. 
3.2.10 Powder X-ray diffractometry (PXRD) 
Morphology of the powder samples was investigated using a Benchtop X-ray 
diffraction instrument, model Miniflex 600 (Rigaku, Woodlands, TX) with primary 
monochromated radiation (CuK radiation source, l = 1.54056 Å). The instrument was 
operated at an accelerating voltage of 40 kV and 15 mA. All samples were subjected to the 
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same program (scanned over a 2q range of 5° to 40° at a step size of 0.04°/sec and a dwell 
time of 2 sec), scan speed 1°/min. 
3.2.11 Differential scanning calorimetry (DSC) 
Thermal properties of formulations were conducted using a modulated differential 
scanning calorimetry (mDSC) (model Q20, TA Instruments, New Castle, DE) equipped 
with a refrigerated cooling system. Each sample of approximately 3 mg was loaded into a 
standard aluminum pan and press-sealed with an aluminum lid (PerkinElmer, Waltham, 
MA). Another crimped empty pan was used as a reference. Experiments were performed 
at a heating ramp rate of 10°C/min in the range of 30-250°C with a modulation temperature 
amplitude of  1°C/min under dynamic flow of  nitrogen purge the sample cell at a flow rate 
of 40 mL/min. Data was analyzed using TA Universal Analysis 2000 software (TA 
Instruments, New Castle, DE).  
3.2.12 Determination of water sorption isotherm 
Isotherms of peptide-bound water were determined for lyophilized formulations 
using dynamic vapor sorption (Surface Measurement Systems Ltd., London, UK). A quartz 
pan was loaded with approximately 10 mg of the lyophilized powder. Water was absorbed 
from the samples prior to assay, and was removed by leaving the samples at below 0.5% 
RH until mass changed by less than 0.002% in dm/dt for 120 min. Each formulation was 
run for a full sorption/desorption cycle from 0% to 90% RH in steps of 10% RH at 25°C. 
The instrument was run in step dm/dt mode reach equilibrium, as determined by a dm/dt 
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less than 0.0075% within an interval of 5 min. Percentage of change in mass was calculated 
and plotted as sorption isotherm. The following equation was used to calculate percent 
mass sorption (desorption).  
mass% sorption (desorption) =   #$%&'()'	(,'%&'()')	#$	.())	/0&.	1(2'&	)0&32#0$	(,')0&32#0$).())	0/	,&4	301,'&	(2	#$#2#(5	'67#5#8&(2#0$	(9%	;<) 100  
3.2.13 Long-term stability study (mannitol- and lactose-based formulations) 
To avoid exposure to humidity, the lyophilized CSP7 with mannitol and lactose 
cakes (1:5, 1:70 and 1:140) in the sealed vials were wrapped with parafilm and aluminum 
foil and kept in a desiccator in the fridge. After 10-month storage, the cakes were 
reconstituted and analyzed by HPLC as describe in section 3.2.2. 
3.2.14 Nebulization of peptide 
The lyophilized CSP7: sugar (mannitol and lactose) in the molar ratio of 1:140 and 
1:70, respectively were freshly reconstituted with SWI (concentration of 0.5 mg/mL). The 
solutions were atomized using two types of vibrating mesh nebulizers, which are 
Aeroneb® Pro (Aerogen, Mountain View, CA) and EZ Breathe® Atomizer (Model EZ-
100, Nephron Pharmaceuticals Corporation, Orlando, FL). Nebulization was performed 
until dryness. Each atomized sample was collected by condensation in the polypropylene 
tube (35) and analyzed by HPLC as described in section 3.2.2.  
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3.3 RESULTS AND DISCUSSION 
3.3.1  Preformulation studies  
A common challenge of formulating biopharmaceutical products is their instability. 
Peptide drugs may exhibit a wide range of aggregation phenomena along with chemical 
instability (41,42). At this relatively early stage of product development, the chemical 
stability and aggregation of the CSP7 peptide were evaluated at different conditions (Figure 
3.1). Figure 3.1A shows the effect of agitation on recovery of CSP7 after shaking at 5°C 
and 25°C for 24 hours. The level of the peptide decreased about 4% after 24 hours of 
shaking at both temperatures. The solutions were still clear and colorless. Peptide 
aggregation was not detected. The assessment of repeated freeze-thaw cycles on quality of 
the CSP7 solution was also conducted. Figure 3.1B shows that about 100% of the CSP7 
remained after 5 freeze-thaw cycles. No aggregation was found in any samples following 
5 freeze-thaw cycles. These results indicate that freeze-thaw cycling did not affect the 
stability of CSP7 solution. In addition, Figure 3.1C shows that the storage temperature 
(from -80 to 25°C) only slightly affected the stability of CSP7 up to 48hours. The extent 
of CSP7 decreased about 3% after storage at 25°C for 48 hours but it was more stable at 
lower temperatures and shorter storage periods. At -80°C and -20°C, the remaining CSP7 
was about 100% after storage for 48 hours. There was no aggregation or precipitation 
detected in any sample after reconstitution in 2 mL of SWI.  These results clearly indicate 
that CSP7 being lyophilized, dissolved at neutral pH or frozen is stable for a short time at 
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wide range of temperatures. Next, the effect of excipients (mannitol and lactose) on long-
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Figure 3.1: Effect of agitation (A), freeze-thaw cycles (B), storage temperature (C) on 










































3.3.2 Appearance and residual moisture content of lyophilized cakes 
The lyophilized CSP7-mannitol (1:70 and 1:140) and CSP7-lactose (1:70) 
formulations produced smooth and homogeneous cakes. The cakes maintained their 
structure when tapped and did not exhibit collapse or melt-back after storage at 5°C. The 
lyophilized products of neat CSP7 without bulking agent and the 1:5 molar ratio of both 
excipient-based formulations showed a loss of pore structure and broke into pieces while 
the CSP7-lactose (1:140) cake had minimal shrinkage. Behavior of the lyophilized cake 
significantly affects the stability of the formulations. Proper cake formation results in 
proper pore formation, which is associated with water escape and moisture content in the 
product (43). Compared to the cake, which remains in the microstructure, collapsed mass 
may contain a higher level of residual moisture since the specific surface area of the 
shrunken structure is decreased (44).  
The residual moisture content from the freshly prepared cakes was in the range of 
0.49-4.02% w/w. Overall, residual moisture content of the mannitol- and lactose-based 
formulations were similar except for the CSP7-lactose (1:140), which contained the highest 
moisture content (4.02% w/w) approximately 8-fold greater than that of the mannitol-based 
cake of the same molar ratio (0.53% w/w). The difference in residual moisture content 
resulted from poor structure and improper pore formation of the CSP7-lactose (1:140) 
cakes. Generally, lyophilized peptides are more stable at lower water content (< 3%) since 
high levels of residual moisture frequently lead to higher molecular mobility and chemical 
instability in the solid state of the protein and peptide (28,45,46). These results demonstrate 
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that lyophilization of CSP7 alone or with mannitol or lactose (1:5 or 1:70) result in effective 
removing of moisture from the formulations.  
3.3.3 Chemical stability of peptide in reconstituted solution 
Figure 3.2A shows the stability of CSP7 in reconstituted solutions. Potency, which 
refers to the amount of peptide in the sample, remained at about 100% after 8 hours at 5°C 
and 25°C. It is important to obtain isotonic solution after reconstitution of the lyophilized 
formulations. The non-isotonic solutions can cause the release of histamine, which resulted 
from changing of the osmotic load around mast cells (47). The release of histamine is 
responsible for bronchoconstriction (48). Osmolality of the reconstituted solutions of 
lyophilized CSP7 containing mannitol or lactose was 378 and 328 mOsm/kg (slightly 
hypertonic). The osmolality of DBPS and solutions of mannitol and lactose in water were 
294, 98, and 47 mOsm/kg, respectively. The osmolality of DPBS and sugar solutions were 
thus very close to the osmolality of the reconstituted CSP7-bulking agent solutions. 
Although the CSP7 reconstituted solutions were slightly hypertonic, using vibrating mesh 
nebulizers for drug delivery can markedly improve the treatment time and dose delivery 
(49).  
3.3.4 Chemical stability of peptide in lyophilized state with mannitol 
A plot of the percentage remaining CSP7 (potency) versus time is presented in 
Figure 3.2B. The results show that CSP7 was quite stable in the lyophilized state for 4 
weeks at 5°C (98.6%) and 25°C (96.8%). The reconstitution times were between 50-55 
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seconds and the pH of the samples was about 8. Stability results indicated that the CSP7 in 
lyophilized cakes containing mannitol (1.5% w/v; 1:140) can resist chemical degradation 
in the solid state for up to 1 month. In addition, there was no significant change in 
osmolality (range between 374-378 mOsm/kg) throughout the study period. Residual 
moisture content of the samples increased from 0.5% at initial to 1.21% and 0.92% after 
storage at 5°C and 25°C, respectively, however, aggregation of the peptide was not 
detected when reconstituted after 1-month storage. Thus, storage of mannitol based 
formulations without exposure to moisture results in both excellent chemical stability of 

















































Figure 3.2: Chemical stability data of reconstituted CSP7 solutions after storage at 5°C 
and 25°C for 8 hours (A), and of lyophilized cakes after storage at 5°C and 
25°C for 4 weeks. (B) 
3.3.5 Long term stability of the lyophilized CSP7-bulking agent cakes 
To test long term stability of CSP7 cakes in the absence of moisture a set of cakes 
of different formulations was kept at 5°C in a desiccator. Thus, the cakes were protected 
from humidity during this stability study to avoid an increase of moisture content. After 10 
months at 5°C cakes were reconstituted and analyzed for CSP7 using HPLC, as described 
under Materials and Methods.  The results of the analysis (Figure 3.3) demonstrate high 
stability of the lyophilized cakes of CSP7 with mannitol (1: 70 and 1:140) or lactose (1:5; 
















mannitol (1:5) cakes (not shown) after reconstitution. Thus, this formulation was not 
analyzed. The other solutions (Figure 3.3) were clear and colorless. Figure 3.3 shows that 
the percent potency of the samples were between 92.7% (± 1.0) and 97.4% (± 1.9). 
Regarding this study, without exposure to humidity, the CSP7-bulking agent formulations 
(except CSP7-mannitol 1:5) were sufficiently stable at 5°C for up to 10 months.  
These results demonstrate that mannitol and lactose protect more than 92% of CSP7 
up to 10 months at 5°C without exposure to moisture and any of formulations shown in 
Figure 3.3, if stored properly, could be used for further in vivo studies of CSP7. On the 
other hand, an increase in moisture content in the cake during storage was associated with 
the lower Tg of the protein formulations. (32,50). The decreased Tg led to an increase in 
molecular mobility, crystallization of the bulking agent and protein instability (32). Thus, 
water vapor most likely transferred from around the rubber stoppers could affect the 
stability of the peptide. Indeed, at 8 weeks, the moisture content of samples stored at 5°C 
and 25°C without desiccator increased further to 1.99% and 1.36%, respectively. 
Moreover, both samples exhibited turbidity upon reconstitution due to formation of 
insoluble aggregates, similar to those observed after 10 months at 5°C in formulation with 
mannitol (1:5). As the aggregates were observed in the cakes containing higher moisture 
content, the moisture-induced aggregation became concerned. Water sorption can increase 
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molecular mobility which leads to a change of physical structure (22). Therefore, the effect 
of moisture on structure of the cake and aggregate formation of CSP7 was further studied. 
 
Figure 3.3: Chemical analysis of CSP7-bulking agent after 10-month storage without 
exposure to humidity at 5°C, no data of CSP7-Mannitol (1:5) presented due 
to its aggregation (n=3) 
3.3.6 Determination of water sorption isotherm  
To evaluate ability of different formulations of CSP7 to absorb moisture, water 
absorption/desorption isotherms were determined as described under Materials and 
Methods. Figure 3.4A and 3.4B display the water sorption/desorption isotherms of the 
lyophilized CSP7 formulations containing mannitol and lactose, respectively. In general, 











material adsorbs water molecules only at the surface, while amorphous organic solids have 
glassy state that allows water to diffuse through them as well as onto the surface. This 
theory coincides with our water sorption/desorption isotherms. The almost unchanged 
weight of bulk materials indicated that the bulk mannitol and lactose monohydrate were 
non-hygroscopic and in their crystalline state, which adsorbed minimal water vapor onto 
only their surface. On the other hand, the significant weight changes of the lyophilized 
formulations determined that they were hygroscopic solids. Figure 3.4A shows the 
sorption/desorption cycles of the lyophilized neat CSP7 and CSP7 with mannitol or lactose 
(1:5 molar ratio) formulations. The isotherm patterns showed that the lyophilized neat 
CSP7 rapidly absorbed considerable quantities of moisture at high %RH (70-90%RH) and 
that the lowest level of bulking agents (1:5) slightly affected the moisture sorption of CSP7. 
Lyophilized CSP7-excipient formulations at all three molar ratios showed that the higher 
CSP7-excipieint molar ratio, the less water was absorbed (Figure 3.4B and 3.4C). We 
hypothesize that the higher the level of bulking agent, the more interactions can occur 
between peptide and bulking agents occur. At 1:70 and 1:140, the water sorption of both 
mannitol- and lactose-based formulations was lower than the neat CSP7. Moreover, at the 
same molar ratio, the lactose-based formulation adsorbed much less water than the 
mannitol ones. This can be attributed to the greater chemical interaction between CSP7 and 
lactose than the mannitol. Once the hydrogen bonds between CSP7 and bulking agents are 
formed there are less functional groups available for water to interact with the peptide and 
the less water capable of bine absorbed. Sorption isotherms of CSP7-lactose formulations 
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showed that the lactose-based formulations began adsorbing moisture at about 40% RH. 
This is attributed to the amorphous state of the formulations. The CSP7-lactose 1:5 
formulation showed the highest percentage mass change. Rates of moisture sorption of the 
1:70 and 1:140 were slower as a function of % RH, which may result from recrystallization 





































Figure 3.4:  Sorption and desorption isotherms of lyophilized neat CSP7 and lyophilized 
CSP7:mannitol formulations (A), and CSP7:lactose formulations (B) 
3.3.7 Effect of bulking agent on moisture-induced lyophilized CSP7 aggregation 
Data shown in Figure 3.4 demonstrate that exposure of CSP7 cakes to moisture 
during storage results in an increase in the moisture content and, potentially, this can affect 
stability of CSP7 and induce crystallization of the bulking agent.  Based on the results 
shown in Figure 3.4, a 12 hour exposure to 75% RH at 25°C was selected as the condition 
for further evaluation of the effect of moisture on structure of the cake and CSP7 stability.  
To investigate the effect of the bulking agents, lactose and mannitol, on aggregation of 
lyophilized CSP7 formulations, three drug-excipient molar ratios (1:5, 1:70 and 1:140) 







bulking agents since they likely exhibit different physical states (crystalline and 
amorphous) after lyophilization. Exposure of the cakes to 75% RH at 25°C for 12 hours 
resulted in a significant (up to an order of magnitude) increase in the moisture content 
(Figure 3.5).   
3.3.8 Moisture content after exposure to high humidity environment 
Karl Fischer titration (Figure 3.5) measured the moisture content of lyophilized 
CSP7-bulking agent formulation before (previously discussed in section 3.3.2) and after 
exposure to 75% RH at room temperature for 12 hours. The results showed that lyophilized 
neat CSP7 absorbed considerably moisture after exposure to 75% RH. The moisture levels 
of mannitol- and lactose-based formulations decreased when the amount of bulking agents 
increased. At the same molar ratio, the lactose-based formulations tended to absorb more 
moisture than the mannitol-based ones. This was attributed to the addition of amorphous 
lactose. The amorphous sugars usually absorb water into their bulk structure (51). At the 
molar ratio of 1:5, mannitol and lactose-based formulations show higher moisture content 
than the lyophilized neat CSP7, however, there was no statistically significant difference 
between the formulations with bulking agents and neat CSP7 (p > .05). The formulations 
containing less mannitol exhibited greater moisture content. This can be explained since 
the 1:5 mannitol-based formulation contained amorphous mannitol, which absorbed more 
moisture than either the 1:70 and 1:140 formulations which contained a higher degree of 
recrystallized mannitol.   
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Such a significant (p < .05) increase in the moisture content (up to 36-fold for 
CSP7-Mannitol 1:70 formulation) upon exposure to 75% RH (Figure 3.5) can reflect 
formation of crystals in the cakes. It is known that moisture induced crystallization of 
bulking agents, such as mannitol, or inorganic salts, affects chemical stability of proteins 
and peptides as well as promote their aggregation (24,27,30,52,53). To test this hypothesis 
lyophilized cakes exposed to 75% RH were analyzed using PXRD and DSC. Lyophilized 
cakes of the same formulations, which have not been exposed to 75% RH, were used as 





















3.3.9 Powder X-ray diffraction (PXRD) analysis  
Figure 3.6 shows the X-ray diffractograms of the lyophilized CSP7-stabilizing 
agent formulations, bulk materials, and lyophilized neat peptide without bulking agent. The 
sharp peaks at 2q = 32° and 26° present in all lyophilized samples are phosphate crystal 
peaks from the DPBS, which is used as solvent buffer in the formulations (54).  
The XRD results of neat CSP7 and the mannitol containing formulations are shown 
in Figure 3.6A. Bulk mannitol as purchased was in b crystalline form and is shown as 
spectrum “a” while the crystalline mannitol a polymorph is shown as spectrums “b”. The 
XRD diffractogram of d mannitol is not shown, however, its predominant peaks at 9.7°, 
14.5°, 19.7°, 20.5° and 24.8°, 2θ have been reported (55).  The lyophilized neat CSP7 in 
DPBS before and after exposure to 75% RH were amorphous (spectra “c” and “d”). The 
lyophilized CSP7-mannitol (1:5) formulation was partially transformed to its amorphous 
state therefore, very low intensity peaks of d mannitol were observed (spectrum “e”) (56). 
The XRD patterns of the 1:70 and 1:140 molar ratio of the mannitol-based formulations 
(spectrum “g” and “i”) indicate the mixtures of polymorphs of crystalline mannitol. The 
peaks of d, a and b mannitol are present. Intensity of the crystalline mannitol peaks (at 
9.7°, 14.5°, 19.7°, 20.5° and 24.6°; Figure 3.6A) increased as the amount of mannitol in 
the formulation was increased. Based on the XRD data acquired in this study, b mannitol 
was predominantly transformed to mixtures of d (and/or a) polymorphs after 
lyophilization. In addition, the peak at 9.7°, and 18°, 2θ may be the peaks of mannitol 
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hemihydrate, which is the crystalline fraction within the freeze-dried products, and this 
hydrate is metastable and prone to lose water at room temperature easily (55,57). As a 
result, water can interact with the peptide and induce aggregation. After exposure to 75% 
RH, the major peaks of d, a (and/or hemihydrate form) mannitol were smaller or no longer 
so apparent while the intensity of the b polymorph peaks increased (spectrum “f”, “h” and 
“j”). The results indicate that unstable polymorphic forms of crystalline mannitol are 
converted to the more stable b form when moisture in the cakes is increased.  Formation 
of crystalline mannitol coincided with an increase in the moisture in the formulation 
(Figure 3.5) and with aggregation of CSP7 upon reconstitution of the lyophilized cakes. 
Figure 3.6B shows the XRD results of CSP7-lactose formulations. The absence of 
crystalline lactose patterns (peaks 12.5, 20 and 21.5, Figure 3.6B) indicated that amorphous 
lactose was fully formed at all CSP7-lactose molar ratios following lyophilization (spectra 
“d”, “f” and “h”). Amorphous lactose in the 1:5 CSP7-lactose formulation remained 
unchanged after exposure to 75% RH (spectrum “e”); whereas the crystalline lactose 
developed in the 1:70 and 1:140 formulations after exposure to 75% RH (spectrum “g” and 
“i”). Thus, similar to mannitol, lactose recrystallization was also induced by water absorbed 
during 12h exposure to 75% RH.  Thus, an increase in the moisture in the cake (Figure 3.5) 
induces crystallization of bulking agents and inorganic buffer salts, which could 







Figure 3.6:  PXRD of CSP7:bulking agent; CSP7:mannitol (A), CSP7:lactose (B), 
before (a, b, d, f, and h) and after exposure to 75% RH (c, e, g and i) 
 










































































































3.3.10 Differential scanning calorimeter (DSC) analysis 
DSC is used to detect crystallization of various organic materials including 
excipients (58). In this study, we focus on the endothermic peaks indicating such events as 
phase transitions, conformational changes or thermal decomposition of crystal hydrates. 
Figure 3.7A-D show the effect of exposure to 75% RH on DSC thermograms of the CSP7-
mannitol and lactose formulations. The melting peak of peptide was not present indicating 
the amorphous state. As mentioned earlier, CSP7 formulations were prepared in DPBS 
buffer, which consists of sodium chloride (NaCl), potassium chloride (KCl), dibasic 
sodium hydrogen phosphate dihydrate (Na2HPO4.2H2O) and monobasic potassium 
phosphate (KH2PO4). There are various studies reporting the effects of buffer salts on 
crystallinity of the bulking agents, such as delayed lactose crystallization, polymorphic 
behavior of mannitol, or inhibition of mannitol crystallization (59–62).  
DSC data of the CSP7-mannitol formulations before exposure to 75% RH showed 
that the low extent of crystalline mannitol in the CSP7-mannitol formulation at the lowest 
molar ratio (1:5) was present as a very small endothermic peak at 135°C. This melting 
endotherm indicated the endothermic transition of mannitol polymorphism (59). A similar 
peak was observed such that the melting point of d mannitol was detected at 139°C or 
136°C, when mannitol was prepared in mixtures with inorganic salts 10% w/w of NaCl 
and KCl, respectively. These melting temperatures are different from the melting point of 
pure d mannitol reported as 155°C (59). Even though the d polymorph is difficult to 
produce, it frequently occurs in freeze-dried materials (59). 
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DSC thermograms of the higher CSP7-mannitol molar ratios of 1:70 and 1:140 
showed melting endotherms of mannitol at 145°C and 150°C, respectively (Figure 3.7A). 
These results were comparable to those reported by Telang et al. (2003) (59). Shifting of 
melting temperatures of the bulk to processed mannitol from 168 °C to 150 °C can be 
explained by the impact of NaCl on polymorphism of mannitol. The melting point of 
mannitol when mixed with NaCl was depressed since NaCl had melt miscibility with 
mannitol (59). The endothermic temperature of CSP7-mannitol (1:70) formulation (145°C) 
was 5°C lower than that of the reported value of lyophilized mannitol with NaCl. This may 
be due to the additional effect of salts from DPBS present in the lyophilized sample. For 
the 1:140 molar ratio formulation, the melting point of the formulation was 150°C since 
this sample contained a higher amount of b mannitol and less d form and amorphous 
mannitol (Figure 3.6). It has also been reported that potassium phosphate salts inhibit 
crystallization of mannitol during the cooling step of lyophilization (63). However, 
KH2PO4 contained in the DPBS buffer used in our study is much less than the NaCl amount. 
Thus, the crystalline inhibition effect from this salt may be concealed by the effect of the 
NaCl. 
Following exposure to 75% RH for 12 hours, the DSC thermograms of the CSP7-
mannitol (1:5) lyophilized formulation showed the broad endothermic event from 90-
130°C. This peak probably corresponds to the melting endotherm of crystalline mannitol 
shifted in the presence of water. The previous study also reported that in the presence of 
water, the broad endothermic event at temperature lower than the melting point of mannitol 
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crystals was attributed to the temperature-depressed melting of anhydrous crystalline 
mannitol (55). The endothermic peaks at 148°C were determined in the other two mannitol 
formulations (1:70 and 1:140). The DSC results confirmed the XRD data, indicating that 
before and after exposure to 75% RH, moisture induced crystallization of mannitol, 
observed by XRD (Figure 3.6). The small amount of the unstable form of crystalline 
mannitol in the 1:5 was more difficult to detect by DSC. 
The DSC curve of bulk lactose monohydrate shows three distinct endothermic 
peaks at 146°C, 219°C and 245°C, representing the dehydration of lactose monohydrate, 
melting, and decomposition temperatures of lactose crystalline lattice, respectively (64). 
After lyophilization, the dehydration endotherm was absent from all CSP7-lactose 
formulations. DSC thermograms of the CSP7-lactose 1:70 and 1:140 formulations showed 
a small melting endotherm at ~195°C (Figure 3.7B), which most likely reflects the DSC-
induced lactose recrystallization at elevated temperature. Notably, crystallization of lactose 
was not detected by XRD without heating the cake (Figure 3.6B).  
After exposure to 75% RH, the CSP7-lactose (1:5) formulation showed a relaxation 
endotherm from the amorphous lactose at 120°C (65). The 1:70 and 1:140 exhibited two 
distinct endothermic transitions at about 146°C and a broad endothermic event between 
160-210°C, which represented the dehydration of lactose monohydrate and the melting 
lactose (64). These results were in good agreement with the XRD data (Figure 3.6), which 
indicated that the physical state of the materials (crystallization) depended on the relative 
amount of lactose in the formulations. 
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Figure 3.7:  DSC thermograms of lyophilized  CSP7:bulking agent before (A and C) and 
after exposure to 75% RH for 12 hours (B and D); mannitol based 
formulations ((1) and (2)) - bulk mannitol (a), a mannitol (b), lyophilized 
neat CSP7 (c), 1:5 (d), 1:70 (e), 1:140 (f) and lactose based formulations 
((3) and (4)) - bulk lactose monohydrate (a), lyophilized neat CSP7 (b), 1:5 












































































































































As shown in the PXRD and DSC data, after lyophilization, all CSP7-lactose 
formulations were amorphous and in the anhydrous form. Therefore, at the same molar 
ratio, the lactose-based cakes had greater water update than CSP7-mannitol cakes. This 
was described previously (31), where amorphous lyophilized lactose/peptide cakes had 
greater moisture affinity than those containing mannitol. The stability of protein/peptide 
products can be affected by crystallization of excipients during freeze-drying (66). Thus, 
possible mechanisms of CSP7 aggregation as well as properties of aggregates were 
evaluated next using chemical assay and other analytical methods.   
3.3.11 Moisture-induced aggregation of lyophilized CSP7 (mannitol- and lactose-
based formulations) is reversible 
First, the formation of aggregates induced by moisture in both mannitol- and 
lactose-based formulations was investigated. After exposure of lyophilized CSP7 
formulations to 75% RH for 12 hours followed by reconstitution with SWI, turbid solutions 
containing aggregates were obtained. The reconstituted solutions of CSP7-mannitol 
formulations appeared notably more turbid than the lactose-based formulations. The 
aggregates were isolated by centrifugation and resuspended in DPBS and dissolved by 
adjusting pH to approximately 8.0 by addition of small amount (less than 1% v/v) of 
ammonium hydroxide. CSP7 in re-dissolved aggregates was characterized by HPLC, 
LC/MS and MALDI-TOF MS as described in Materials and Methods. Neither of methods 
has detected CSP7 multimers proving that the aggregation is reversible and that the soluble 
aggregates were converted to soluble monomeric species of the peptide. Since degradation 
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products of the CSP7 were not found, aggregation does not affect chemical stability of 
CSP7. Previous studies have reported that physical protein/peptide aggregates could be 
reversible by adjustment of solvent properties such as pH, and/or temperature (67–69). 
CSP7 consists of four threonines, which contain hydroxyl groups, and are considered to be 
a strong water-binding residue (70). These water-binding sites on the peptide molecule lead 
to water adsorption when the peptide is exposed to a high moisture environment (71). The 
amino acids, which contain weak water-binding sites can also contain sorbed water (70). 
Reversing CSP7 aggregation by adjusting pH with ammonium hydroxide can indicate 
stabilization of aggregates by protonated N-terminal amino group. However, an increase 
in the ionic strength by adding NaCl up to 2 M did not result in dissolving the aggregates 
(not shown). Therefore, hydrophobic interactions likely significantly contribute to 
stabilization of CSP7 aggregates. Chemical assay was used next to quantitate CSP7 
aggregation in moisture exposed formulations with different molar ratios of mannitol and 
lactose.  
3.3.12 Chemical assay of the aggregates 
Two types of clear solutions obtained from the supernatants (1), and the solutions 
of re-dissolved aggregates (2) were tested by HPLC and LC/MS in order to determine 
distribution of CSP7 between solution and solid phase after reconstitution of different 
formulations exposed to 75% RH. Figure 3.8 shows the results of these analyses as the 
relative percent of each sample as compared to the freshly prepared samples (100%). The 
total percent recovery of CSP7 from solutions (1) and (2) was nearly 100%, demonstrating 
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that after reconstitution all CSP7 is distributed between solution and aggregates and 
confirming that the moisture-induced aggregates of CSP7 are a reversible type. The 
fraction of aggregates (Figure 3.8) of CSP7 from the mannitol-based formulations (~50%) 
were substantially greater than that of the lactose-based formulations (~2.4-14.7%). The 
lyophilized neat CSP7 formulation exhibited the highest aggregation (~58%) since there 
was no stabilizing agent to protect the peptide from aggregation. It indicates that the peptide 
itself tends to aggregate. The percentage of aggregates in the mannitol containing 
formulations was not significantly different. The amount of mannitol in the CSP7-mannitol 
(1:5) formulation is not sufficient to protect the peptide from aggregation while 
recrystallization of mannitol in the 1:70 and 1:140 formulations reduced the stabilizing 
effect of mannitol. Amounts of CSP7 aggregates in lactose-based formulations were ranked 
from high to low as follows: 1:5, 1:140 and 1:70, respectively. Aggregation of CSP7 in the 
1:70 formulation was lowest since this formulation was amorphous. The CSP7-lactose 
(1:5) formulation was also amorphous. However, the greater extent of aggregation may 
result from an insufficient stabilizing property of lactose at this low level. Aggregates of 
peptide in the 1:140 formulation were attributed to the initial high residual moisture 
content, which can induce peptide aggregation prior to exposure to 75% RH. Two 
mechanisms can explain this phenomenon, including physical properties of the bulking 
agents during lyophilization and interactions between bulking agents and CSP7.   
The results agreed with a previous study by Herman et al. (1994), which proposed 
that the effect of water on amorphous drugs does not depend on the amount of water 
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present, but rather on where it is located. In a lyophilized formulation, mannitol crystallizes 
either during lyophilization or storage depending on the ratio of mannitol to drug (72). 
There is not a significant amount of water associated with crystalline mannitol as shown in 
the sorption/desorption isotherms of bulk mannitol (crystalline) (72). The prior studies also 
reported similar results; as the crystallinity of mannitol increases, its stabilizing effect is 
reduced (25,27,73,74). When mannitol recrystallizes with time, water in the lyophilized 
material redistributes and results in an increase in the free water in the drug 
microenvironment since mannitol is non-hygroscopic and cannot acts as a “sink” for the 
liberated water (16,66). On the other hand, all lactose formulations remained in their 
amorphous state after lyophilization. Amorphous lactose may act as an internal desiccant 
to absorb water into itself therefore, water would not be available to interact with the 
peptide, resulting in significantly less aggregates formed. Oliyai et al. (31) similarly found 
that amorphous lactose decreased the number of free water molecules available for 
chemical reaction with the peptide as compared to the mannitol containing systems. 
Moreover, lactose also has a much higher Tg than mannitol therefore, it can better retain 
its glassy state of the formulations with exposure to increased moisture.  
An alternative (synergistic) mechanism is interaction between CSP7 and bulking 
agent. CSP7 containing a high portion of threonine is also able to form intermolecular 
hydrogen bonds such as crosslinking (75). Mannitol obviously did not affect aggregation 
since crystallization of mannitol during lyophilization was not able to form hydrogen 
bonding to the dried protein (32). In contrast, an increase in the molar excess of lactose 
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almost completely removed aggregation. Interactions of sugars (lactose or trehalose) with 
dried proteins was investigated (76). The study provided evidence that not only hydrogen 
bonding occurred between the stabilizing agent-protein, but also that sugar binding is 
essential for sugar-induced stabilization of protein during lyophilization and rehydration. 
Moreover, it was conjectured that the hydroxyl groups of bulking agents bond (acting as 
hydrogen acceptors and donors) with proteins. Therefore, the sugar serves as “water 
substitutes” to insure conformational stability (77). Finally, lactose, as a reducing sugar, 
could potentially stabilize peptide in the solution by forming a Schiff base (28,41,78) due 
to a reaction with N-terminal amino group of CSP7. Since a Schiff base is reversible, its 
formation should not affect the biological activity of CSP7, and could serve as a reservoir 
for the peptide in vivo. Based on these results, it appears that lactose stabilized CSP7 
against moisture induced aggregation in the solid state to a greater degree than mannitol. 
In summary, while both pH adjustment and using lactose (1:70 or more) prevented CSP7 




Figure 3.8:  Chemical analysis of aggregates CSP7-bulking agent after exposure to 75% 
RH at room temperature for 12 hours, (n=2) 
3.3.13 Effect of nebulization on chemical stability of CSP7 
Both CSP7 formulations stored without exposure to moisture with mannitol (1:140) 
and lactose (1:70) easily dissolved in SWI. As compared with the initial bulk solution 
before lyophilization, the chemical stability of CSP7 was not affected by sterile filtration 
or lyophilization (recovery nearly 100%). Chemical stability of the CSP7 from mannitol 
and lactose containing formulations following nebulization by Aeroneb® Pro nebulizer/EZ 










clearly indicate that efficiency of the vibrating mesh nebulizers; Aeroneb® Pro and the EZ 
Breathe® was comparable and that nebulization of CSP7 solutions were not significantly 
different. The nebulization conditions (e.g., shear and temperature from the nebulizers) did 
not affect the chemical stability of CSP7. Moreover, stability of the peptide was not 
significantly decreased by the aerosol cloud collection technique (e.g., peptide did not 
adsorb onto the surface of the collecting tube) and the degradation products and aggregates 
of the CSP7 were not detected after nebulization.  
3.4 CONCLUSION 
Lyophilized CSP7 absorbed moisture, which induced its aggregation. Even though 
the aggregates are reversible by pH adjustment, once they are formed, it lead to a decrease 
in chemical stability. Amorphous lactose performed remarkably superior to crystallized 
mannitol in terms of preventing peptide aggregation. Lactose possibly had a significant 
interaction with amino acids containing in CSP7 exhibiting the stabilizing effect. Long-
term stability study indicated the stable formulations and a suitable storage condition for 
the lyophilized CSP7. While this study determined that 1:70 CSP7:lactose formulation is 
optimal for long-term shelf storage, possible differences between biological activity of 
mannitol and lactose formulations will be evaluated in the next step by in vivo comparison 
of moisture free CSP7 formulations.  Nebulization using vibrating mesh nebulizers did not 
affect the potency of the peptide.  This optimized formulation is useful in an upcoming in 
vivo study. The mechanisms between lactose and CSP7 in increasing the stability of the 
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Chapter 4: Optimal Nebulizer for Inhaled Tissue-Type Plasminogen 
Activator (tPA) and Single-Chain Urokinase Plasminogen Activator 





Tissue-type plasminogen activator (tPA) and single-chain urokinase plasminogen 
activator (scuPA) have attracted interest as enzymes for the treatment of inhalational 
smoke-induced acute lung injury (ISALI). In this study, the use of commercial human tPA 
and lyophilization for the preparation of scuPA and subsequent delivery in liquid form 
using vibrating mesh nebulizers (VMNs) with the appropriate droplet size for pulmonary 
delivery were demonstrated. Aeroneb® Pro (active) and EZ Breathe® (passive) VMNs 
were used to nebulize the reconstituted solutions of commercial lyophilized human tPA 
and lyophilized scuPA formulations. Both the Aeroneb® Pro and EZ Breathe® nebulizers 
produced atomized protein solutions with droplet sizes smaller than 5 µm, which is 
appropriate for pulmonary delivery. However, the Aeroneb® Pro nebulizer produced 
smaller droplets than the EZ Breathe® nebulizer. The enzymatic activity of both tPA and 
scuPA was maintained at more than 50% after nebulization of the 0.5 mL solutions. The 
Aeroneb® Pro nebulizer performed slightly better than the EZ Breathe®. Gel 
electrophoresis did not reveal any degradation products or protein aggregates of the tPA. 
scuPA maintained nearly 100% of its specific enzyme activity. The loss of the proteins 
from nebulization is attributed to the residual volume of solutions in the medication cup. 
Additionally, enzyme activity of tPA and scuPA was not significantly affected by other 
excipients, sterile filtration, lyophilization process or the reconstitution.  
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4.1 INTRODUCTION 
Tissue-type plasminogen activator (tPA) and urokinase plasminogen activator 
(uPA) are fibrinolysins, which are proteins that have been used clinically for the treatment 
of various types of thrombotic disorders with symptoms such as submassive pulmonary 
embolism (1), pleural effusions (2–4), myocardial infarction (MI) (5), ischemic stroke (6–
8), deep vein thrombosis (9,10), and acute respiratory distress syndrome (ARDS) (11–14). 
Severe burns and smoke exposure develop ARDS in many patients, which is a severe form 
of acute lung injury (ALI) that has a high mortality rate (30–40%), long-term morbidity 
(15), and requires protracted hospitalization. Inhalational smoke-induced ALI (ISALI) is 
one form of ALI, and it is characterized by severe airway obstruction, fibrinous airway 
casts or debris, and alveolar fibrin deposition (16). Due to its long-term morbidity and high 
mortality, an efficient and specific treatment for ISALI would have a positive impact on 
patients. Previous studies have reported that human tPA suppresses activator-induced 
neutrophil superoxide anion production and has an anti-inflammatory effect on ARDS in 
an animal model (17,18). tPA is an endogenous serine protease that is found in pleural 
effusions and cleaves to plasminogen and generates active plasmin; this activity can 
dissolve thrombosis associated with MI and stroke (19,20). It has also been proven that 
airway fibrin in a murine model of asthma was dissolved and bronchospasm was relieved 
by airway administration of tPA (21). The most effective route of tPA delivery for ARDS 
treatment is direct administration to the airway (19). However, the possibility of direct 
pulmonary delivery of tPA must be studied further before using this approach (19).  
uPA is also found in pleural effusions and potentially useful for ARDS treatment 
as well. The nebulization of uPA decreased lung fibrosis in rabbits with bleomycin-induced 
injury (22). Both the upregulation of uPA and the downregulation of plasminogen activator 
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inhibitor-1 (PAI-1) attenuated the accelerated fibrosis in ALI with accelerated pulmonary 
fibrosis induced by bleomycin (BLM) (23). An inactive form of uPA, single-chain uPA 
(scuPA), resists inhibition by PAI-1. A preliminary study reported by the University of 
Texas Health Science Center at Tyler (UTHSCT) as well as other literature strongly 
suggests that a recently developed fibrinolysin, scuPA, is advantageous for ISALI, and they 
hypothesized that scuPA should be more effective and safer than tPA (24,25). It was 
reported that scuPA exerts relatively low amount, but it has a durable fibrinolytic activity, 
and it is effective in clearing intrapleural fibrin in rabbits (20,26). 
Another potential alternative approach for the local treatment of this respiratory 
disease is the pulmonary delivery of peptides and proteins directly to the lung. This allows 
for lower doses and low systemic side effects (27). Nebulization is one of the techniques 
for airway and pulmonary delivery of protein and peptide drugs in solution or suspension 
forms. However, after only a few minutes of nebulization, the proteins may denature, which 
reduces its activity, forms protein aggregates, and increases immunogenic potential (28). 
These effects may result from excessive stress on the proteins in the droplets and the bulk 
reservoir. Therefore, testing the nebulization process is a significant step in the 
development of pulmonary protein delivery.  
Although a large number of biologic products are successfully used for various 
treatments, Pulmozyme® is the only biopharmaceutical product for pulmonary delivery 
available in the market (28). Moreover, there are no inhaled products of plasminogen 
activators on the market. Some of the major challenges are the sufficiency and 
reproducibility of the aerosol deposition, its distribution in the airway due to the complexity 
of lung geometry, the clearance mechanism, and the uncontrollable breathing of the patient 
(28). Additionally, generation of the aerosol plume should prevent the activity loss of 
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biopharmaceutics and not damage their fragile structure (28). User acceptance and patient 
compliance must also be taken into consideration, as demonstrated by the failure of 
Exubera® (29–31). Owing to many characteristics (e.g., higher molecular weights, 
multiple functional groups, 3-dimensional structures of proteins), formulation of these 
biologics becomes more challenging than small molecules (32). The specific and fragile 
properties of these proteins cause difficulties in processing, storage, and delivery (33,34). 
The achievement of protein formulation requires that their enzymatic activity persists 
during every step of development. Most of these proteins are not stable in liquid form (35) 
and are more stable as solids (36). Hence, lyophilization is always a preferred type of 
processing that can prolong the stability of the protein to provide sufficient a shelf-life for 
commercial products  (37–39).  
The objective of this study was to evaluate the optimal nebulizer for further use in 
vivo studies of tPA and scuPA. In addition, for the scuPA, optimal formulation and optimal 
lyophilization conditions were also determined. The results of these studies support the 
further development of a protein formulation for the inhibition of epithelial apoptosis and 
pulmonary fibrosis of the lung.  
 
4.2 MATERIALS AND METHODS 
4.2.1 Materials 
Human recombinant tPA (Cathflo® Activase® was purchased form Genentech, 
Inc., South San Francisco, CA). scuPA (purity 73% activity) was a generous present from 
UTHSCT (Tyler, TX). D-mannitol was purchased from Thermo Fisher Scientific Inc. 
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(Bridgewater, NJ), and Dulbecco’s phosphate buffered saline (DPBS) was purchased from 
Lonza (Walkerville, MD). BSA was purchased from Sigma-Aldrich (St. Louis, MO) and 
human plasmin (PL) was purchase from Haematologic Technologies, Inc. (Essex Junction, 
VT). Urokinase was obtained from Sekisui Diagnostics (Lexington, MA), and Pefachrome 
uPA (Bz-β-Ala-Gly-Arg-pNA-AcOH) and Pefachrome tPA were bought from Pentapharm 
(Switzerland). The tcuPA activity standard (100,000 IU/mg) was purchased from Sekisui 
Diagnostics (Lexington, MA). NuPAGE® Novex® Bis-Tris Mini Gels (Life 
Technologies, Carlsbad, CA) and 96-well plates were purchased from Thermo Fisher 
Scientific Inc. (Bridgewater, NJ). Other chemical reagents and solvents used were of 
analytical grade.  
4.2.2 Solid-state preparation of scuPA 
Lyophilization to prepare freeze-dried scuPA. In brief, a bulk solution of scuPA in 
DPBS containing 500 μg/mL of scuPA and 1.5% w/v of mannitol were prepared and 
sterilized by filtration through 0.2 µm of a surfactant-free cellulose acetate (SFCA) sterile 
syringe filter (Corning Inc., Corning, NY). The effect of filtration was also examined. A 
half mL of the filtrate was placed in a borosilicate glass vial and lyophilized it using a 
VirTis Advantage Lyophilizer (VirTis Company Inc., Gardiner, NY). Lyophilization cycle 
parameters were previously developed by Coldstream Laboratories, Inc. (40), as shown in 
(Table 4.1). The lyophilized cakes were stored at 5°C until nebulization.  
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Step Temperature Hold Time Pressure Ramp 
(°C) (min) (mTorr) (°C/min) (min) 
Loading 5 60 — — — 
Freezing −55 120 — 0.50 120 
Annealing −15 120 — 0.50 80 
Freezing −55 240 — 0.50 80 
Evacuation −55 10 100 — — 
Primary drying −30 TBD 100 0.10 250 
Secondary drying 30 240 100 0.08 720 
Table 4.1: Lyophilization cycle parameters 
4.2.3 Karl Fischer titration   
Measurement of residual moisture content in the scuPA cakes was demonstrated by 
Karl Fischer titration using the Aquatest 2000 moisture analyzer (Photovolt Instruments, 
Minneapolis, MN). A sealed glass vial containing a lyophilized scuPA cake was accurately 
weighed. Anhydrous methanol (1 mL) was pre-weighed and added to the sealed sample 
vial by syringe through the rubber stopper and mixed. An aliquot was withdrawn and 
transferred to the Karl Fischer vessel. The empty vial, including the stopper and the 
aluminum seal, were washed, dried, and reweighed. The moisture content of 1 mL 
anhydrous methanol was subtracted from the samples. Percentage of residual moisture 
content (%w/w) was calculated based on the weight of the cake. Moisture analysis was 
performed in duplicate for each sample. 
4.2.4 Osmolality measurements 
Osmolality of the protein solutions were performed on a 5004 Micro-osmetteTM 
High Sensitivity Osmometer (Precision Systems Inc. Natick, MA) with 50 µL sample 
volume. The equipment was calibrated using the osmometry standard solutions of 100 and 
500 mOsm/kg H2O (Precision Systems Inc., Natick, MA) before measurement. The 
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osmolality of the reconstituted scuPA solution in sterile water for injection (SWI), DBPS, 
and a solution of mannitol in SWI were measured in triplicate. 
4.2.5 Droplet size distribution 
Reconstituted solutions of tPA and scuPA were atomized using the VMNs (EZ 
Breathe® and Aeroneb® Pro atomizers). The solutions were added to the nebulizer 
directed towards a vacuum line, positioned horizontally. The reservoir of the Aeroneb® 
Pro nebulizer, attached to a T-shaped mouthpiece, and the reservoir and mouthpiece of the 
EZ Breathe® atomizer were parallel to the ground. The nebulizers were placed 2.5 cm from 
the center of the laser beam, and the aerosol cloud that was produced crossed the beam at 
a distance of 2.5 cm from the instrument. The aerosol was drawn through the laser beam 
using the applied vacuum. The droplet size distribution was measured using a laser 
diffractometer (HELOS, Sympatec GmbH, Clausthal-Zellerfelg, Germany). The two-tail 
t-test was used to compare the particle size distribution at 50%, x(50). 
4.2.6 Nebulization of tPA and scuPA solutions 
A commercial human recombinant tPA, Cathflo® Activase®, and lyophilized 
scuPA were freshly reconstituted with SWI. The tPA and scuPA solutions were prepared 
at concentrations of 200 μg/mL and 250 μg/mL, respectively. The solution of 0.5 mL was 
atomized using VMNs, which are Aeroneb® Pro (Aerogen, Mountain View, CA) and EZ 
Breathe® Atomizer (Model EZ-100, Nephron Pharmaceuticals Corporation, Orlando, FL). 
Nebulization was performed until the aerosol cloud was no longer produced. Each 
atomized sample was collected by condensation technique in the polypropylene tube, as 
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described in the previous study (41). The samples collected were stored at 4°C until 
analysis. 
4.2.7 Kinetic activity assay 
The activity of tPA and scuPA was determined as described in the technical report 
(42). tPA and uPA were determined from the kinetic changes in the absorbance at 405 nm 
of the chromogenic tPA and uPA substrates (Pefachrome) in 0.1% BSA in a PBS buffer. 
Samples were prepared by mixing the aliquots with the buffer and diluted as a series (a 
total volume of 100 μL) in the 96-well plates. In each well, equal volumes of the 
chromogenic substrate solutions were added in the same buffer, Pefachrome tPA (0.2 mM) 
and Pefachrome uPA (0.1 mM), then mixed and incubated them at ambient room 
temperature. Kinetic readings were obtained at 405 nm every minute for a minimum of 30 
min by a Varian Cary Eclipse fluorescence spectrophotometer equipped with a 96-well 
plate reader accessory (Varian, IL). The data from a fitted linear equation were obtained 
from the Varian software.  
Before adding the scuPA to the plate, scuPA had to be activated using plasmin in 
the nanomolar ratio of a final scuPA-to-plasmin ratio of approximately 50:1. Then, it was 
incubated in the tubes at 37°C for 3 hours. Inactivated samples (controls) were prepared 
using the same technique, but a BSA-PBS buffer without plasmin was used instead. 
Samples in 96-well plates were analyzed. The ability of proteins to cleave human 
plasminogen to the active plasmin product were reported as enzymatic activity in arbitrary 
units (AU). The results were calculated based on standards of known activity, which were 
Cathflow® Activase® and standard tcuPA. The activity of tPA and scuPA in the pre- and 
post-nebulized samples was calculated as a relative percent as compared with the initial 
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solutions (with a coefficient of variation £ 10%). In addition, protein activity before and 
after sterile filtration, after lyophilization, and after the reconstitution of the scuPA 
formulated product were also analyzed.  
4.2.8 Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
analysis 
The sample solutions of tPA or scuPA (6.5 µL and 7.5 µL for reduced and non-
reduced samples, respectively) were mixed with 2.5 μL of concentrated (“4X”) NuPAGE® 
lithium dodecyl sulfate (LDS) sample buffer. One uL of NuPAGE® Reducing Agent 
(“10X”) was added to the reduced samples. All samples were heated at 90°C for 2 min, 
then 10 µL of each sample was loaded and separated on 4–12% NuPAGE® Novex® Bis-
Tris gels. SDS running buffer was prepared by adding 50 mL of 20X NuPAGE® MES 
SDS running buffer to 950 mL of deionized water. The gel was conducted at 200 V for 35 
min in MES SDS running buffer, and protein bands were visualized by SimplyBlue™ 
SafeStain (Thermo Fisher Scientific, Waltham, MA). The gels were imaged by a Bio-Rad 
molecular imager (Bio-Rad Laboratories, Inc., Philadelphia, PA). Intensity of the bands 
was visually observed. 
4.2.9 Residual volume of Aeroneb® Pro nebulizer 
Geometric analysis and measurement of enzymatic activity of tPA and scuPA were 
used to determine the proteins in the medication cup. A dried, empty medication reservoir 
from the Aeroneb® Pro nebulizer and a collecting tube were weighed before filling the 
DPBS. Various volumes of DPBS (0.5 mL, 1 mL, 2 mL, 3 mL, 5 mL, and 8 mL) were 
loaded into the reservoir, then weighed and nebulized until the aerosol cloud was no longer 
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produced. The reservoir with the residual solution and the tube with the collected sample 
were then re-weighed. Each volume was tested in triplicate. The difference in weight before 
and after nebulization was calculated as the percentage of residual solution, the percentage 
of solution collected, and the percentage of solution loss. 
 
Initial	weight = cup + loading	solution − 	empty	cup    Equation 1 
%	residual	solution = 	 {(%73V&')#,7(5	)0572#0$)	W	'.324	%73}
Y$#2#(5	1'#Z[2
			×	100     Equation 2 
%	solution	collected = 	 {(278'V)0572#0$	%055'%2',)	W	'.324	278'}
Y$#2#(5	1'#Z[2
			×	100   Equation 3 
%	solution	loss = %	residual	solution	 − %	solution	collected   Equation 4 
Five mL of the tPA and scuPA solutions of 0.2 mg/mL and 0.25 mg/mL, 
respectively; were nebulized and tested by enzymatic assay. The activity of proteins in the 
residual solutions in the medication reservoir and the solutions collected in the tubes were 
compared with the initial solutions before nebulization (100%). Each sample was tested in 
duplicate. 
4.3 RESULTS AND DISCUSSION 
4.3.1 Appearance of lyophilized cakes, residual moisture content, and tonicity of 
scuPA formulation 
The lyophilized scuPA with mannitol formulation produced homogeneous cakes, 
which maintained their structure when tapped and did not exhibit collapse or melt-back. 
This supports the use of 1.5% w/v mannitol as the bulking agent is sufficient to provide the 
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appropriate cake structure. The appearance of the lyophilized products significantly could 
affect their stability. Proper cake formation results in proper pore formation, and this is 
associated with water escape and the moisture content of the product (43). Moisture 
determination indicated that the residual moisture content of the lyophilized scuPA was in 
the range of 0.6–0.8% w/w, which is in the target range of < 3% w/w (44). Generally, 
lyophilized biopharmaceutics are more stable at lower water content, since high-level 
residual moisture frequently leads to higher molecular mobility and in turn induces 
chemical instability in the solid state of proteins and peptides (36,45,46).  
The osmolality of the reconstituted solution of scuPA was 400 mOsm/kg 
(hypertonic). The osmolality of DBPS and the mannitol solution in water was 294 
mOsm/kg and 90 mOsm/kg, respectively. The total osmolality of these solutions was close 
to the osmolality of the reconstituted solution. The non-isotonic solutions can cause the 
release of histamine, which results from the changing of the osmotic load surrounding the 
mast cells (47). The release of histamine is responsible for bronchoconstriction (48). 
However, using VMNs for drug delivery markedly improved the treatment time and dose 
delivered. Thus, VMNs have the potential to enhance patient tolerability and adherence to 
the nebulized therapeutics of the hypertonic solutions (49).  
4.3.2 Droplet size distribution 
The main goal of nebulization is to deliver the drug formulation to the lungs. 
Although several factors affect pulmonary drug delivery, such as the patient’s age, the 
patient’s lung function, and the stage of the disease; the particle size of the inhaled 
formulation is one of the most important features that determines its deposition in the 
airway. VMNs have higher nebulization efficiency than jet or ultrasonic nebulizers in terms 
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of aerosol droplet size, which relates to deposition characteristics (50). Even though no 
baffle was needed, both active and passive VMNs generated very fine aerosol droplets (50). 
In general, the smaller droplets are more likely to reach the distal parts of the lung (51,52). 
Droplets larger than 5 µm would likely be deposited in the upper airways, while droplets 
of the optimum droplet size of 3–5 µm would likely be deposited in the tracheobronchial 
tree (53). Figure 4.1A and 4.1B show the aerosol droplet size distribution of tPA and scuPA 
formulations, respectively. The droplet size, x(50), of tPA and scuPA atomized from the 
EZ Breathe® were 4.68 µm and 4.94 µm, respectively, which is significantly larger (p < 
.05) than those from the Aeroneb® Pro nebulizer (3.68 µm and 3.70 µm, respectively). 
These differences are possibly due to the different designs of the nebulizer; EZ Breathe® 
is the passive type, while the Aeroneb® Pro is an active vibrating mesh device. However, 



















Figure 4.1:  Droplet size distribution of tPA solutions (A) and scuPA solutions (B) by 




4.3.3 Nebulization of tPA and scuPA 
The various types of nebulizers are categorized according to their mechanism of 
atomization, such as jet nebulizers, ultrasonic nebulizers, and VMNs (28). Jet nebulizers 
and ultrasonic nebulizers, by design, suffer from recirculation. The droplets were nebulized 
at least 10–15 times, which caused an increase in interfacial stress (54,55). VMNs, 
however, are single-pass devices by design, which prevents the repetition of nebulization 
stress (56). Moreover, ultrasonic nebulizers generate heat during operation that is not 
suitable for heat-labile drugs such as proteins or peptides (57), while VMNs do not generate 
heat (58). VMNs have also been recommended for aerosolized protein and peptide 
formulations due to factors of protein degradation and inactivation (59–61). Therefore, 
vibrating mesh nebulization is the expected choice in this study for use with tPA and 
scuPA, since this method can gently generate the aerosol plume (62,63) with low shear 
force (64).  
The Cathflow® Activase® and scuPA cakes rapidly dissolved in SWI. Figure 4.2 
and 4.4 present the biologic activities of tPA and scuPA before and after nebulization. The 
relative percentages of tPA following nebulization by Aeroneb® Pro and EZ Breathe® 
nebulizers were 54.9% and 53.7%, respectively; while 57.4% and 56.6% of scuPA were 
determined, respectively. For both proteins, the Aeroneb® Pro nebulizer exhibited slightly 
greater activity than the EZ Breathe®. In addition, polyacrylamide gel electrophoresis was 
used to verify the extent of tPA (Figure 4.3). The band intensity of samples after 
nebulization were visually lighter than the samples before nebulization (100%, initial). 
Moreover, degradation products and aggregates of the tPA in the samples were not detected 
on the gels. The measured activity and band intensity of tPA show strong correlation 
between enzyme activity and protein loss. In addition, the activity of scuPA was not 
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significantly affected by the addition of mannitol to the formulation with sterile filtration 
or the lyophilization process. The band intensity of samples from each device was less 
intense than the bulk sample, the sample after filtration, and the reconstituted sample before 
nebulization (data not presented). Loss of both proteins and the corresponding loss of 
enzyme activity was not significantly decreased due to nebulization. These results show 
that nebulizing conditions (i.g. solution formation, and the effect of the atomizing process 
of the nebulizers) did not have an influence on the activity of either protein. However, it 
was hypothesized that the majority of the loss of enzymes in this in vitro study was 
attributable to the residual solution that remained in the medication container. Therefore, a 
study of the residual solution in the nebulizer cup was conducted. 
 
 
Figure 4.2: Enzymatic activity of tPA after nebulization by Aeroneb® Pro and EZ 
Breathe® nebulizers 
Human tPA (Cathflo® Activase®) 
Reconstitute with SWI
Pre-nebulization














Figure 4.3: SDS-PAGE results of tPA samples before and after nebulization by 
Aeroneb® Pro and EZ Breathe® nebulizers (n=2)  
 
 
Figure 4.4: Enzymatic activity of scuPA after sterile filtration, lyophilization, and  
nebulization by Aerone® Pro and EZ Breathe® nebulizers as compared with 































       Samples 
1 reconstituted tPA solution (Initial)  
2 tPA solution after nebulization using EZ Breathe®-1  
3 tPA solution after nebulization using EZ Breathe®-2  
4 tPA solution after nebulization using Aeroneb® Pro-1  
5 tPA solution after nebulization using Aeroneb® Pro-2  
NR = non-reduced samples, R = reduced samples 
 
scuPA bulk solution in DPBS










4.3.4 Residual solution remaining in the medication cup 
The Aeroneb® Pro nebulizer was used in this study because of its slightly better 
performance. Figure 4.5A plots the weight difference between the dried empty containers 
(medication cup and polypropylene tube) and the containers with DPBS (density = 1.01 
g/mL) based on gravimetric analysis. The weights of residual DPBS in this study were in 
the range of 0.17–0.52 mg. These results agree with previous reports, in which the residual 
volume was between 0.2 mL and 0.4 mL (58,65). Compared with the weight of the loading 
solution (Equation 2), the percentage of the residual solution that remained in the cup of 
the 0.5 mL loading volume was the highest (~ 37%), and the residual solution was 
decreased when the loading volume increased. The residual weight of the 8 mL loading 
solution was only about 4%.  
The enzyme activity of the proteins that remained in the cups and collected in the 
polypropylene tubes after nebulization of 5 mL of each protein solution was measured and 
compared to the sample before nebulization (Figure 4.5B). The activity of the residual 
proteins (tPA and scuPA) in the cup was 6.2% and 8.8%, respectively, and the activity in 
the collecting tube was 93.9% and 88.4%, respectively. The results by gravimetric method 
show that a mass of 7.4% remained in the cup, and 90.8% of the solution was collected in 
the tube following nebulization of the 5 mL DPBS buffer. These mass percentages agree 
with the enzymatic activity of each fraction of the proteins. Therefore, this supports our 
premise that the loss of protein activity of tPA and scuPA in the samples collected was not 
affected by nebulization using the Aeroneb® Pro, but rather it was attributable to the loss 
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         (B) 
Figure 4.5: (A) Mass (%) of residual DPBS solution in medication reservoir, collected 
solution in collecting tube, and lost mass (n=3), (B) enzymatic activity of 
tPA and scuPA of the residual solution in the medication reservoir, collected 
solution in collecting tube, and lost activity (n=2). 
36.9 32.9 26.0
12.3 7.4 4.1 3.8
61.0 64.4 71.1














































Reconstituted solutions of lyophilized tPA and optimized scuPA formulation can 
be delivered to the lungs for the treatment of ISALI by nebulization using VMNs. For 
inhaled drugs targeted to the lung, a small droplet size and the appropriate adjustment of 
the nominal dose are both important for obtaining high treatment efficiency and for 
avoiding the risk of overdose. Therefore, further studies on pulmonary dose delivery using 
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Appendix A.: Proteins in perfluorocarbon suspensions  
 
A.1 tPA in perfluorocarbon suspensions for endotracheal tube drug delivery 
A.1.1 MATERIALS AND METHODS 
A.1.1.1 Materials 
Human recombinant tPA (Cathflo® Activase® was purchased form Genentech, 
Inc., South San Francisco, CA). scuPA (Lot No. 071407A, purity 73% activity), 3.5 mg/mL 
was kindly obtained from UTHSCT (Tyler, TX). Perfluorocarbons, Perfluorodecalin 
(PFD) and Perflubron (PFB), were purchased from FluoroMed, L.P. (Round Rock, TX). 
10 mm endotracheal (ET) tube.  
 
A.1.1.2 Methods 
tPA was suspended in two types of PFCs (PFD and PFB) (0.2 mg/mL). Each 
suspension was kept in 5°C refrigerator for 24 hours, and then left it at 25°C for 2 hours. 
The suspensions were placed at 37°C in an incubator for 15 minutes and then injected into 
the ET tube at 37°C.  The passed-tube sample was collected and stored at 37°C for another 
30 minutes. Sample was kept at 5°C until analyzed. Enzymatic activity was tested by 














A.2 scuPA in perfluorocarbon suspensions  
A.2.1 MATERIALS AND METHODS 
A.2.1.1 Material 
scuPA (Lot No. 071407A, purity 73% activity), 3.5 mg/mL was kindly obtained 










































































































Figure A.3:  Activity of scuPA in PFB suspensions following gentle shaking for 30, 60 

















Appendix B.: Delivery of tPA and scuPA into a cold 1 gallon plastic bag 
with vibrating mesh nebulizer and mechanical ventilator 
 





Figure B.1: Ventilation circuit setting 
 
 
Figure B.2: Experimental design 
Setting:
Experimental design:
• Nebulization of 4 mg of the enzyme in 8 ml under 
• ventilation into a zip 1 gallon plastic bag .
• Tidal volume 100 ml
• Three work stations (three ventilators) with different settings
Colors (1=blue, 2=green, 3=red) correspond to the symbols at box-plots:
• # Oxygen, % Humidifier Repeats
• tPA scuPA* 
• 1 21 + 2 2
• 2 21 - 2 2
• 3 100 + 2 2
* An additional Exp (n=1 for each Station, scuPA) was run with 10 ml PBS added to the bag 












Figure B.4: Samples collection 
 
Ventilator’s Settings for Stations
1 2 3
Three Samples were Collected from Each Run
1. “NEU” – an aliquot prior to the nebulizer
2. “WASHES” – and aliquot of 200 ml (4x50 
ml) saline, which was used to wash all 
the ventilator tubes and combined.
3. “BAG” – an aliquot from the plastic 
zipped bag. 
Working hypothesis:  
Protein: “NEU”=“WASHES” + “BAG”














Figure B.6: Nebulization results in a decrease in the protein concentration in the bag 
 
Analysis: Amidolytic Activity&Protein Concentration (BCA) were measured 
in the Samples and expressed as Box Plots (separate for tPA and scuPA)
1. Nebulization results in a decrease in the 










Figure B.8: A fraction of the enzymatic delivered to the bag 
2. Only a fraction of the initial enzymatic 
activity present in the bags and tube washes
TPA scuPA
3. Only a fraction of the activity was delivered to 
the bag. Significant activity has “disappeared”
TPA scuPA
Could Reflect Inactivation of the Enzyme
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Figure B.10: Effect of nebulization and 100% oxygen on specific activity of the proteins  
 
 
4. Nebulization results in a decrease in the 
"concentration” of the enzymatic activity
TPA scuPA
5. Neither nebulization nor 100% oxygen (red) 





Figure B.11: Enzymatic activity of proteins collected in a bag with 10 mL DPBS 
 
 
Figure B.12: Enzymatic activity of proteins collected  
6. PBS (10 ml) in a bag does not improve delivery of scuPA. 
7. Correlation between concentration of protein and 
activity.
scuPA, PBS experiment scuPA&TPA
8. Balance of Protein (BCA)
TPA scuPA










Figure B.14:  Effects of nebulization using vibrating mesh nebulizer and mechanical 
ventilator on enzymatic activity of tPA and scuPA 
9. Changes in the Specific Activity due to Nebulization
TPA scuPA
Conclusions
• There was no significant decrease in the specific activity of the enzymes due 
to nebulization
• There was no significant inactivation of the enzymes by 100% oxygen
• There was a decrease in the enzyme concentration in the bag
• Only a small fraction of the activity&protein was detected in the bag
• Significant part of activity and protein was lost during nebulization. If the 
losses were associated with the enzymes escaping the ventilation circuit, 
that may be harmful to  the personnel. 
• An additional experiment(s) may be needed to determine the routes of the 
loss of the enzymes. 
• Washing (200 ml) ventilator tubes after animal nebulization and following 
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